Sanara Medtech Inc
Buy, Hold or Sell?

Let's analyse Sanara Medtech Inc together

Penke I guess you are interested in Sanara Medtech Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Sanara Medtech Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Sanara Medtech Inc

I send you an email if I find something interesting about Sanara Medtech Inc.

Quick analysis of Sanara Medtech Inc (30 sec.)

What can you expect buying and holding a share of Sanara Medtech Inc? (30 sec.)

How much money do you get?

$0.00

When do you have the money?

1 year

How often do you get paid?

22.5%

What is your share worth?

Current worth

$5.22

Expected worth in 1 year

$5.56

How sure are you?

55.0%

+ What do you gain per year?

Total Gains per Share

$0.34

Return On Investment

1.0%

For what price can you sell your share?

Current Price per Share

$32.35

Expected price per share

$26.06 - $35.01

How sure are you?

50%

1. Valuation of Sanara Medtech Inc (5 min.)

Live pricePrice per Share (EOD)

$32.35

Book Value per Share

$5.22

Intrinsic Value Per Share

$-5.33 - $-1.65

Total Value Per Share

$-0.11 - $3.57

My calculation of the intrinsic value of Sanara Medtech Inc is based how much money is coming from the company's main activities (Free Cash Flow).

The following numbers are based on moving averages and per share and per quarter.
I use a 6% discount rate for the low estimation and 3% for the high estimation.
The current Free Cash Flow Per Share is 10Y: ($-0.08) 3Y: ($-0.16) TTM: ($-0.10)
The change per quarter (trend) of the Free Cash Flow Per Share is 10Y: ($0.00) 3Y: ($0.00) TTM: ($-0.01)

Years	Total Low est.	Total High est.	Added Free Cash Flow
1	$-0.64	$-0.30	$-0.67 - $-0.30
2	$-1.25	$-0.57	$-0.68 - $-0.27
3	$-1.84	$-0.80	$-0.69 - $-0.24
4	$-2.41	$-1.01	$-0.70 - $-0.22
5	$-2.95	$-1.18	$-0.71 - $-0.19
6	$-3.47	$-1.33	$-0.72 - $-0.16
7	$-3.96	$-1.44	$-0.73 - $-0.13
8	$-4.44	$-1.54	$-0.75 - $-0.11
9	$-4.90	$-1.61	$-0.76 - $-0.08
10	$-5.33	$-1.65	$-0.77 - $-0.05

2. Growth of Sanara Medtech Inc (5 min.)

Is Sanara Medtech Inc growing?

	Current year	Previous year	Grow	Grow %
How rich?	$44.5m	$37.5m	$5.1m	12.2%

How much money is Sanara Medtech Inc making?

	Current year	Previous year	Grow	Grow %
Making money	-$1.1m	-$4.9m	$3.7m	323.7%
Net Profit Margin	-7.3%	-40.5%	-	-

How much money comes from the company's main activities?

Quarterly Yearly

3. Financial Health of Sanara Medtech Inc (5 min.)

4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)

Industry Rankings (Medical Instruments & Supplies)

Richest
#123 / 169

Most Revenue
#117 / 169

Most Profit
#117 / 169

Most Efficient
#118 / 169

What can you expect buying and holding a share of Sanara Medtech Inc? (5 min.)

Welcome investor! Sanara Medtech Inc's management wants to use your money to grow the business. In return you get a share of Sanara Medtech Inc.

What can you expect buying and holding a share of Sanara Medtech Inc?

First you should know what it really means to hold a share of Sanara Medtech Inc. And how you can make/lose money.

Speculation

The Price per Share of Sanara Medtech Inc is $32.35. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

The fundamentals: the financial health trends of Sanara Medtech Inc.
The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Sanara Medtech Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $5.22. Based on the TTM, the Book Value Change Per Share is $0.08 per quarter. Based on the YOY, the Book Value Change Per Share is $0.34 per quarter.
You may receive quarterly/yearly dividend in the form of additional shares.
You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.

Based on historical numbers we can estimate the returns while holding a share of Sanara Medtech Inc.

How much money are you going to get?

	MRQ		TTM		YOY		5Y		10Y
	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share	$	% of Price per Share
Usd Eps	-0.03	-0.1%	-0.13	-0.4%	-0.23	-0.7%	-0.16	-0.5%	-0.10	-0.3%
Usd Book Value Change Per Share	0.06	0.2%	0.08	0.3%	0.34	1.0%	0.25	0.8%	0.14	0.4%
Usd Dividend Per Share	0.00	0.0%	0.00	0.0%	0.01	0.0%	0.00	0.0%	0.00	0.0%
Usd Total Gains Per Share	0.06	0.2%	0.08	0.3%	0.35	1.1%	0.26	0.8%	0.14	0.4%
Usd Price Per Share	41.10	-	38.40	-	31.13	-	27.31	-	13.69	-
Price to Earnings Ratio	-369.74	-	-138.48	-	-281.94	-	-123.43	-	-61.25	-
Price-to-Total Gains Ratio	715.58	-	-331.20	-	-57.18	-	-259.34	-	-129.06	-
Price to Book Ratio	7.87	-	7.68	-	7.13	-	9.52	-	4.37	-
Price-to-Total Gains Ratio	715.58	-	-331.20	-	-57.18	-	-259.34	-	-129.06	-

When do you get the money?

Usd Investment	$.00
Usd Price Per Share	32.35
Number of shares	30

Gains per Quarter	Trailing 12 Months	5 Year
Usd Dividend Per Share	0.00	0.00
Usd Book Value Change Per Share	0.08	0.25
Usd Total Gains Per Share	0.08	0.26
Gains per Quarter (30 shares)	2.52	7.75
Gains per Year (30 shares)	10.08	31.01

Years	Return on Investment (TTM)			Return on Investment (5Y)
	Dividend	Book Value gain	Total gains	Dividend	Book Value gain	Total gains
Broker costs	-	-	-10	-	-	-10
1	0	10	0	0	31	21
2	0	20	10	1	61	52
3	0	30	20	1	92	83
4	0	40	30	2	122	114
5	0	50	40	2	153	145
6	0	60	50	3	183	176
7	0	71	60	3	214	207
8	0	81	70	4	244	238
9	0	91	80	4	275	269
10	0	101	90	5	306	300

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %

	Trailing 12 Months				3Y				5 Year				10 Year				ALLTIME
				%				%				%				%				%
Earnings Per Share	0.0	4.0	0.0	0.0%	0.0	12.0	0.0	0.0%	0.0	20.0	0.0	0.0%	7.0	33.0	0.0	17.5%	7.0	81.0	0.0	8.0%
Book Value Change Per Share	2.0	2.0	0.0	50.0%	5.0	7.0	0.0	41.7%	8.0	11.0	1.0	40.0%	17.0	18.0	5.0	42.5%	30.0	46.0	12.0	34.1%
Dividend per Share	0.0	0.0	4.0	0.0%	2.0	0.0	10.0	16.7%	3.0	0.0	17.0	15.0%	9.0	0.0	31.0	22.5%	10.0	0.0	78.0	11.4%
Total Gains per Share	2.0	2.0	0.0	50.0%	5.0	7.0	0.0	41.7%	9.0	11.0	0.0	45.0%	22.0	18.0	0.0	55.0%	36.0	46.0	6.0	40.9%

Fundamentals of Sanara Medtech Inc

About Sanara Medtech Inc

https://sanaramedtech.com
Medical Instruments & Supplies
107
1200 Summit Avenue, Fort Worth, TX, United States, 76102
Google Maps Bing Maps

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. It also provides BIAKOS Antimicrobial Skin and Wound Cleanser, a patented product that contains synergistic ingredients that have been shown to impact mature biofilm microbes; BIAKOS Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing that helps against planktonic microbes, as well as immature and mature biofilms; and BIAKOS Antimicrobial Skin and Wound Irrigation Solution. In addition, it develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement; and VIM Amnion Matrix, a homologous wound covering product. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Fundamental data was last updated by Penke on 2024-04-12 18:39:04.

Financial Health

Profitability Details

	Compared to previous year	Compared to industry
The company is making a loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.

Operating Efficiency Details

	Compared to previous year	Compared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.

Liquidity Details

	Compared to previous year	Compared to industry
The company is able to pay all its short-term debts.
The company is just able to pay all its short-term debts with the most liquid assets.

Solvency Details

	Compared to previous year	Compared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details

	Compared to previous year	Compared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Sanara Medtech Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Measures how much net profit Sanara Medtech Inc earns for each $1 of revenue.

Above 10% is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
A Net Profit Margin of -1.3% means that $-0.01 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Sanara Medtech Inc:

The MRQ is -1.3%. The company is making a loss. -1
The TTM is -7.3%. The company is making a loss. -1

Trends

Current period		Compared to		+/-
MRQ	-1.3%	TTM	-7.3%	+6.0%
TTM	-7.3%	YOY	-40.5%	+33.1%
TTM	-7.3%	5Y	-77.4%	+70.1%
5Y	-77.4%	10Y	-86.6%	+9.1%

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	-1.3%	6.2%	-7.5%
TTM	-7.3%	6.2%	-13.5%
YOY	-40.5%	8.0%	-48.5%
5Y	-77.4%	7.3%	-84.7%
10Y	-86.6%	6.8%	-93.4%

Measures how much net profit Sanara Medtech Inc earns for each $1 of revenue.

Revenue is the amount of profit Sanara Medtech Inc generates before taxes and all other costs. For example, when you buy a cup of coffee it will cost you $3. The company does not earn $3 in profit but also has to pay various costs and taxes to create that cup of coffee. Let's assume the cost of creating a cup of coffee is $1.5.

The $3 you pay for a cup of coffee is called revenue.
The $1.5 that’s left over when all costs to create that cup of coffee (including taxes) are deduced from the revenue is called net profit.

The net profit margin looks at how much net profit Sanara Medtech Inc earns for each $1 in revenue.

How to use net profit margin

Higher profit margin is better (more profit).
Above 10% is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
Can be used to compare companies within the Medical Instruments & Supplies industry.

You typically want a high profit margin. This means that for each $1 in sales, Sanara Medtech Inc makes more profit. This shows the investor how efficiently Sanara Medtech Inc is operating in general and compared to other companies in the same industry. Sanara Medtech Inc operates in the Medical Instruments & Supplies industry.

Why do investors use net profit margin in their analysis

It helps investors to determine the efficiency of Sanara Medtech Inc. If profit margins remain low (compared to the Medical Instruments & Supplies industry mean) and there are no improvements to make in production costs or other areas that might be a warning sign. If profit margins are high that means the company has low overhead costs and is efficiently using its resources to generate profit.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Net Profit Margin of Sanara Medtech Inc is -0.01. This means that Sanara Medtech Inc earned $-0.01 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Net Profit Margin of the Medical Instruments & Supplies industry is 6.2%.
What is the trend?
The trend is important because it shows you how Sanara Medtech Inc is performing over time. The most recent quarter might be important if Sanara Medtech Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sanara Medtech Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare Sanara Medtech Inc with other companies in the same industry (Medical Instruments & Supplies).
Net profit margin should rise over the years.
Can be influenced when Sanara Medtech Inc sells assets (profit will increase while costs remain the same).
It won’t show what part of Sanara Medtech Inc is doing great or needs improvement (it only looks at total revenue and total net income).

How to calculate net profit margin

Net profit margin = net income / total revenue * 100%

Real example of Sanara Medtech Inc

You need the following data to determine net profit margin:

Income statement from the period you want to calculate (for example, MRQ or TTM).

Net income MRQ Sanara Medtech Inc = -237
Total revenue MRQ Sanara Medtech Inc = 17,690
$-237 / $17,690 = -0.01 or -1.3%

Higher is better

The higher the net profit margin, the more efficient the company is generating income. This helps investors to determine how the company is managing money. The net profit margin is an important indicator when diving into the financial health of a company. Overall, you want to see the net profit margin rising over the years. That means the company improved their production and made it more efficient (if possible).

You can use the net profit margin to compare companies within the same industry. If there are two companies where one is much bigger but the smaller one has a higher net profit margin, that means the smaller company is more efficiently using operational costs.

Important: Profit margins can be very different between industries. Companies with assembly lines or transports are much more prone to see shifting in prices for fuel, ingredients and maintenance compared to companies that only provide services. You should never compare net profit margin between different industries.

1.1.2. Return on Assets

Shows how efficient Sanara Medtech Inc is using its assets to generate profit.

Above 5% is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
-0.3% Return on Assets means that Sanara Medtech Inc generated $0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Sanara Medtech Inc:

The MRQ is -0.3%. Using its assets, the company is very inefficient in making profit. -2
The TTM is -1.8%. Using its assets, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-0.3%	TTM	-1.8%	+1.5%
TTM	-1.8%	YOY	-9.5%	+7.6%
TTM	-1.8%	5Y	-8.5%	+6.7%
5Y	-8.5%	10Y	-19.1%	+10.6%

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	-0.3%	1.3%	-1.6%
TTM	-1.8%	1.4%	-3.2%
YOY	-9.5%	1.9%	-11.4%
5Y	-8.5%	2.2%	-10.7%
10Y	-19.1%	2.0%	-21.1%

Shows how efficient Sanara Medtech Inc is using its assets to generate profit.

For a farm, a tractor is considered an asset. The tractor helps ploughing the land making it possible to plant and harvest crops. But the tractor might be old and needing maintenance all the time reducing its efficiency. Return on assets indicates how effectively the farm is using the tractor (and other assets that help the core business) to plough the land.

How to use return on assets

Higher is better.
Above 5% is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on assets in their analysis

Shows the investor how effectively Sanara Medtech Inc is using its resources to generate profit. If the return on assets (-0.3%) from Sanara Medtech Inc are higher than the Medical Instruments & Supplies mean (1.3%) that means Sanara Medtech Inc is using its resources better than their competitors. If not, that means their competitors are more efficient in using their resources to generate profit.

An investor should always look at:

What is the current return on assets?
The current most recent quarter (MRQ) Return on Assets of Sanara Medtech Inc is -0.3%. This means the company generated $0.00 for each $1 in assets.
How does it compare to the industry?
The mean MRQ Return on Assets of the Medical Instruments & Supplies industry is 1.3%.
What is the trend?
The trend is important because it shows you how Sanara Medtech Inc is performing over time. The most recent quarter might be important if Sanara Medtech Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sanara Medtech Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
If a company has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

How to calculate return on assets

Return on assets = net income / total assets * 100%

Real example Sanara Medtech Inc

You need the following data to determine return on assets (ROA):

Income statement
Balance sheet

Net income MRQ (income statement) from Sanara Medtech Inc = -237
Total assets MRQ (balance sheet) from Sanara Medtech Inc = 73,871
-237 / 73,871 = 0.00 or -0.3%

ROA is an important ratio as it will tell you how effectively Sanara Medtech Inc is using its resources to generate profits. Example:

Bob and Kristin both sell ice cream in the summer. They both have an ice cream truck. The truck Bob owes cost him $20.000 and the truck Kristin owes cost her $1500. Over the summer, Bob earned $2000 and Kristin earned $200. To calculate the return on assets:

Bob: $2000 / $20.000 * 100% = 10%
Kristin: $200 / $1500 * 100% = 13.3%

This tells you Bob’s company is more valuable but Kristin's company is more efficient. Be aware that total assets can change over time. A transportation business will buy and sell trucks or planes all the time. Before using return on assets as a guideline, you have to know what the exact assets are. For a company that has many assets changing over time, it’s better to calculate the average assets instead of the total assets.

1.1.3. Return on Equity

Shows how efficient Sanara Medtech Inc is using its investors money to generate profit.

Above 15%-20% is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
-0.5% Return on Equity means Sanara Medtech Inc generated $-0.01 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Sanara Medtech Inc:

The MRQ is -0.5%. Using its investors money, the company is very inefficient in making profit. -2
The TTM is -2.7%. Using its investors money, the company is very inefficient in making profit. -2

Trends

Current period		Compared to		+/-
MRQ	-0.5%	TTM	-2.7%	+2.2%
TTM	-2.7%	YOY	-12.8%	+10.0%
TTM	-2.7%	5Y	-11.1%	+8.4%
5Y	-11.1%	10Y	-1.0%	-10.1%

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	-0.5%	2.6%	-3.1%
TTM	-2.7%	2.8%	-5.5%
YOY	-12.8%	3.7%	-16.5%
5Y	-11.1%	3.9%	-15.0%
10Y	-1.0%	3.9%	-4.9%

Shows how efficient Sanara Medtech Inc is using its investors money to generate profit.

A publicly traded company (any company that issues shares to the public) is owned by its shareholders. Return on equity calculates the amount of profit for every $1 the shareholders invested.

How to use return on equity

Higher is better.
Above 15%-20% is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use return on equity in their analysis

To find out the owners/management's attitude toward their company. You typically want the owners/management to invest in the company and focus on generating profit. If not enough profit is generated (compared to the Medical Instruments & Supplies industry mean), the company might not be investing their money efficiently.

The three steps every investor should look at:

What is the current return on equity?
The current most recent quarter (MRQ) Return on Equity of Sanara Medtech Inc is -0.5%. This means Sanara Medtech Inc generated $-0.01 for each $1 the owners (shareholders) invested.
How does it compare to the industry?
The mean MRQ Return on Equity of the Medical Instruments & Supplies industry is 2.6%.
What is the trend?
The trend is important because it shows you how Sanara Medtech Inc is performing over time. The most recent quarter might be important if Sanara Medtech Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sanara Medtech Inc up to 10 years back (depending if Sanara Medtech Inc existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Does not include intangible assets (non physical assets like licences, computer software, etc.).
Stockholders equity and shareholders equity refer to the same thing.
Liabilities should not be more than three times return on equity.

How to calculate return on equity

Return on equity = net profit / shareholders equity * 100%

Real example of Sanara Medtech Inc

You need the following data to determine ROE:

Income statement
Balance sheet
Net profit MRQ (income statement) Sanara Medtech Inc = -237
Shareholders equity (balance sheet) MRQ Sanara Medtech Inc = 44,832
-237 / 44,832 = -0.01 or -0.5%

A negative shareholder equity is a warning sign. It means the company has more liabilities than assets. It might also mean that the owners did not invest enough money or they are taking money out of the business.

1.2. Operating Efficiency of Sanara Medtech Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Measures how efficient Sanara Medtech Inc is operating .

Measures how much profit Sanara Medtech Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
Above 15% is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
An Operating Margin of -12.3% means the company generated $-0.12 for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Sanara Medtech Inc:

The MRQ is -12.3%. The company is operating very inefficient. -2
The TTM is -11.8%. The company is operating very inefficient. -2

Trends

Current period		Compared to		+/-
MRQ	-12.3%	TTM	-11.8%	-0.5%
TTM	-11.8%	YOY	-28.0%	+16.3%
TTM	-11.8%	5Y	-74.3%	+62.5%
5Y	-74.3%	10Y	-92.2%	+17.9%

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	-12.3%	7.9%	-20.2%
TTM	-11.8%	7.6%	-19.4%
YOY	-28.0%	10.9%	-38.9%
5Y	-74.3%	10.1%	-84.4%
10Y	-92.2%	10.5%	-102.7%

Measures how efficient Sanara Medtech Inc is operating .

The more effecient a company creates products or provides services, the more profit it generates.

How to use operating margin

Higher is better
Above 15% is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries
Can be used to compare companies

Why do investors use operating margin in their analysis

To determine how much profit Sanara Medtech Inc is making from it’s core business.

The three steps every investor should look at:

What is the current net profit margin?
The current most recent quarter (MRQ) Operating Margin of Sanara Medtech Inc is -12.3%. This means that Sanara Medtech Inc earned $-0.12 for each $1 in revenue in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Margin of the Medical Instruments & Supplies industry is 7.9%.
What is the trend?
The trend is important because it shows you how Sanara Medtech Inc is performing over time. The most recent quarter might be important if Sanara Medtech Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sanara Medtech Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Can be calculated in different ways

How to calculate operating margin

Operating margin = operating earnings / total revenue

Real example of Sanara Medtech Inc

You need the following data to determine operating margin:

Income statement
Operating earnings MRQ Sanara Medtech Inc = -2,181
Total revenue MRQ Sanara Medtech Inc = 17,690
$-2,181 / $17,690 = -0.12 or -12.3%

Operating margin is used to calculate how much profit a company makes after variable costs of production but before paying interest and taxes. Some variable costs examples are wages, raw materials, packaging, and transaction fees. The amount of variable costs is different for each company and industry. In general, a higher operating margin is better as this implicates that a company is running efficiently.

For investors, a higher operating margin is a good sign. Although you should always look at operating margin in the long term. If operating margin is fluctuating over the years this might be a sign that things are not running efficiently enough. It’s a way to check how much profit a company is making from its core business.

Operation earnings can be calculated in multiple ways:

Operation earnings = EBIT - non operating income + non operating expense
Operation earnings = Gross profit - operating expense - depreciation and amortisation
Operation earnings = Total revenue - COGS (costs of goods sold) - indirect costs

1.2.2. Operating Ratio

Measures how efficient Sanara Medtech Inc is keeping operating costs low.

Below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
An Operation Ratio of 1.12 means that the operating costs are $1.12 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Sanara Medtech Inc:

The MRQ is 1.123. The company is inefficient in keeping operating costs low. -1
The TTM is 1.118. The company is inefficient in keeping operating costs low. -1

Trends

Current period		Compared to		+/-
MRQ	1.123	TTM	1.118	+0.005
TTM	1.118	YOY	1.280	-0.163
TTM	1.118	5Y	1.737	-0.619
5Y	1.737	10Y	1.843	-0.106

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	1.123	1.153	-0.030
TTM	1.118	1.168	-0.050
YOY	1.280	1.105	+0.175
5Y	1.737	1.097	+0.640
10Y	1.843	1.056	+0.787

Measures how efficient Sanara Medtech Inc is keeping operating costs low.

If the operating ratio is below 1 that means the company is making money. The lower the operating ratio, the more efficient the company.

How to use operating ratio

Lower is better.
Below 1 is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use operating ratio in their analysis

Shows if costs of creating products and or services is increasing or decreasing. The lower the operating ratio, the more efficient the company is creating products and services.

The three steps every investor should look at:

What is the current Operatin ratio?
The current most recent quarter (MRQ) Operating Ratio of Sanara Medtech Inc is 112.3%. This means that Sanara Medtech Inc earned $1.12 for each $1 in net sales in the most recent quarter.
How does it compare to the industry?
The mean MRQ Operating Ratio of the Medical Instruments & Supplies industry is 1.15.
What is the trend?
The trend is important because it shows you how Sanara Medtech Inc is performing over time. The most recent quarter might be important if Sanara Medtech Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sanara Medtech Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
You need COGS to calculate operating ratio which is not always shown in the income statement.
Does not consider debt.

How to calculate operating ratio

Operating ratio = Operating expenses + COGS \ Net sales

Real life example Sanara Medtech Inc

You need the following data to determine operating ratio:

Income statement

COGS is not always specified on the income statement. If so you can use the following calculation:

(cost of revenue + total operating expenses) \ total revenue
(2,883 +16,988) \ 17,690 = 1.12

The operating ratio measures the efficiency of a company at keeping low costs while generating profits from sales. It compares the total operating expenses to the net amount of sales. The total operating expenses exists of:

COGS (materials, labour, rent of facility, repairs)
Operating expenses (legal fees, marketing, wages, rent, maintenance/repairs)

Operating expenses are all the costs the company makes that are not directly tied to the production of the service or product. Where COGS are costs that are directly tied to the production of a product or service.

Do note that COGS is not always available in the income statement. Some companies include COGS in the operating expenses while others list COGS separately. To make it even more confusing, COGS is also known as “costs of sales” and costs of sales is the same as costs of revenue.

The operating ratio tells you how efficient the company is creating its products or services while keeping prices low. In this case, a lower ratio is better. Higher or rising operating ratios might tell you that costs are rising while sales are not improving or staying the same.

1.3. Liquidity of Sanara Medtech Inc.

1.3. Liquidity

1.3.1. Current Ratio

Measures if Sanara Medtech Inc is able to pay off Short-term Debt.

Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
A Current Ratio of 1.38 means the company has $1.38 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Sanara Medtech Inc:

The MRQ is 1.380. The company is just able to pay all its short-term debts.
The TTM is 1.619. The company is able to pay all its short-term debts. +1

Trends

Current period		Compared to		+/-
MRQ	1.380	TTM	1.619	-0.239
TTM	1.619	YOY	2.751	-1.132
TTM	1.619	5Y	3.038	-1.419
5Y	3.038	10Y	2.219	+0.819

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	1.380	2.302	-0.922
TTM	1.619	2.333	-0.714
YOY	2.751	2.588	+0.163
5Y	3.038	2.627	+0.411
10Y	2.219	2.623	-0.404

Measures if Sanara Medtech Inc is able to pay off Short-term Debt.

How to use current ratio

Higher is better
Above 1.5 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
Can be very different between industries
Can be used to compare companies

Why do investors use current ratio in their analysis

Shows if the company can pay of short term debts if needed. A company that can't pay off it's short term debts might get in trouble if they have to pay off their short term debts for whatever reason. For example, markets can change due to global events like covid-19 or the war in Ukraine versus Russia. Because debts are always taken based on future income, it might become troublesome for Sanara Medtech Inc if something happens in the market that will cause sales to plummet.

The three steps every investor should look at:

What is the current current Ratio?
The current most recent quarter (MRQ) Current Ratio of Sanara Medtech Inc is 1.38. This means Sanara Medtech Inc has $1.38 in assets for each $1 in short-term debts.
How does it compare to the industry?
The mean MRQ Current Ratio of the Medical Instruments & Supplies industry is 2.30.
What is the trend?
The trend is important because it shows you how Sanara Medtech Inc is performing over time. The most recent quarter might be important if Sanara Medtech Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sanara Medtech Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Might be deluded.
Not all assets can always be quickly sold.
Can be manipulated by increasing or decreasing the assets and/or liabilities.

How to calculate current ratio

Current ratio = current assets \ current liabilities

Real life example Sanara Medtech Inc

You need the following data to determine operating ratio:

Balance sheet
Current ratio = current assets \ current liabilities
19,006 \ 13,768) = 1.38

The current ratio measures if Sanara Medtech Inc is able to pay short-term debts (obligations). Short term in this context means all debt obligations that are about to expire within one year. The current ratio incorporates current liabilities and current assets. Current assets are all the assets a company has that are expected to be consumed or sold within standard business operations. You can find the current assets in the balance sheet. They consist of:

Inventory
Accounts receivable
Marketable securities
Prepaid expenses
Cash
Cash equivalents
liquid assets

The current liabilities are short term obligations that are due within one year. These consist of:

Short term debts
Dividends
Income taxes
Short-term debts
Accounts payable
Interest payments

The result shows an investor if Sanara Medtech Inc is able to pay all its short-term debts if they were due all at once. When the result of the above formula is below 1, then Sanara Medtech Inc does not have enough capital after selling all its assets to pay all short-term debts. If the ratio drops far below 1 that might indicate Sanara Medtech Inc is or will be in financial trouble anytime soon.

Although this gives an investor some clues, the current ratio may also be deluded. Because owning assets does not mean the company can easily sell them. Also, Accounts receivable may be quite old (they will probably never pay) which deludes the current ratio. As with all ratios, you should only compare them between the same industries and companies.

1.3.2. Quick Ratio

Measures if Sanara Medtech Inc is able to pay off Short-term Debt but only using the most liquid assets.

Above 1 is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
A Quick Ratio of 0.99 means the company can pay off $0.99 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Sanara Medtech Inc:

The MRQ is 0.994. The company is just not able to pay all its short-term debts with the most liquid assets. -1
The TTM is 1.170. The company is just able to pay all its short-term debts with the most liquid assets.

Trends

Current period		Compared to		+/-
MRQ	0.994	TTM	1.170	-0.176
TTM	1.170	YOY	2.288	-1.118
TTM	1.170	5Y	2.684	-1.515
5Y	2.684	10Y	1.777	+0.907

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	0.994	1.098	-0.104
TTM	1.170	1.127	+0.043
YOY	2.288	1.306	+0.982
5Y	2.684	1.430	+1.254
10Y	1.777	1.533	+0.244

Measures if Sanara Medtech Inc is able to pay off Short-term Debt but only using the most liquid assets.

How to use quick ratio

Higher is better.
Above 1 is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use quick ratio in their analysis

Shows how fast Sanara Medtech Inc can pay off its short term debts. This shows if Sanara Medtech Inc can survive emergencies due to market changes or other reasons.

The three steps every investor should look at:

What is the current Quick Ratio?
The current most recent quarter (MRQ) quickRatio of Sanara Medtech Inc is 0.99. This means that Sanara Medtech Inc can pay off $0.99 for each $1 in debt (using most liquid assets).
How does it compare to the industry?
The mean MRQ Quick Ratio of the Medical Instruments & Supplies industry is 1.10.
What is the trend?
The trend is important because it shows you how Sanara Medtech Inc is performing over time. The most recent quarter might be important if Sanara Medtech Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sanara Medtech Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Incorporates only most liquid assets.

How to calculate quick ratio

Quick ratio = cash and equivalents + marketable securities + accounts receivable / current liabilities

Real life example Sanara Medtech Inc

You need the following data to determine operating ratio:

Balance sheet
Quick ratio = cash and short-term investments + short-term investments + netReceivables / total current liabilities
MRQ quick ratio Sanara Medtech Inc: (5,147 + 0 +8,533) / 13,768 = 0.99

The quick ratio measures the same thing as the current ratio, only it uses the most liquid assets a company has. Meaning, the assets that can be sold for cash the easiest and fastest.

As the quick ratio only incorporates the most liquid assets, you should also check the current ratio which also includes less liquid assets. But they may be harder to sell.

1.4. Solvency of Sanara Medtech Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Measures how much % of Sanara Medtech Inc assets are financed with debt.

Below 1 (100%) is considered healthy but always compare Sanara Medtech Inc to Medical Instruments & Supplies industry mean.
A Debt to Asset Ratio of 0.40 means that Sanara Medtech Inc assets are financed with 39.6% credit (debt) and the remaining percentage (100% - 39.6%) is financed by its owners/shareholders.

Let's take a look of the Debt to Asset Ratio trends of Sanara Medtech Inc:

The MRQ is 0.396. The company is very able to pay all its debts by selling its assets. +2
The TTM is 0.354. The company is very able to pay all its debts by selling its assets. +2

Trends

Current period		Compared to		+/-
MRQ	0.396	TTM	0.354	+0.042
TTM	0.354	YOY	0.247	+0.108
TTM	0.354	5Y	0.415	-0.060
5Y	0.415	10Y	1.074	-0.659

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	0.396	0.357	+0.039
TTM	0.354	0.360	-0.006
YOY	0.247	0.353	-0.106
5Y	0.415	0.365	+0.050
10Y	1.074	0.371	+0.703

Measures how much % of Sanara Medtech Inc assets are financed with debt.

When there are more debts than assets, that means creditors have a larger stake Sanara Medtech Inc than its shareholders.

How to use debt to asset ratio

Lower is better.
below 1 (100%) is considered healthy but always compare Sanara Medtech Inc to Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to asset ratio in their analysis

It shows how much debt the company used to finance its assets. If a company is almost entirely financed with debt that means the company might get into serious trouble when emergencies arise like a raise in interest.

The three steps every investor should look at:

What is the current debt to asset ratio?
The current most recent quarter (MRQ) Debt to Asset Ratio of Sanara Medtech Inc is 0.40. This means means that Sanara Medtech Inc is financed with 39.6% credit and the remaining percentage is financed by it's owners (shareholders).
How does it compare to the industry?
The mean MRQ Current Ratio of the Medical Instruments & Supplies industry is 230.2%.
What is the trend?
The trend is important because it shows you how Sanara Medtech Inc is performing over time. The most recent quarter might be important if Sanara Medtech Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sanara Medtech Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry
Some companies can have higher debt to assets ratio's (for example, banks).
Debt to asset ratio should improve over the years.
If the debt to asset ratio is above 1, look at the industry mean and find out why Sanara Medtech Inc has so much debt.

How to calculate debt to asset ratio

Debt to asset ratio = total debt \ total assets

Real life example Sanara Medtech Inc

You need the following data to determine debt to asset ratio:

Balance sheet
Debt to asset ratio = total debt \ total assets
29,283 \ 73,871 = 39.6% or 0.40.

The debt to total assets ratio shows if the company is owned by creditors or shareholders. Or in other words, the total debt in relation to the total amount of assets. It shows how much debt the company used to finance its assets.

1.4.2. Debt to Equity Ratio

Measures if Sanara Medtech Inc is able to pay off its debts by using shareholders equity.

Below 2 is considered healthy but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
A Debt to Equity ratio of 65.3% means that company has $0.65 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Sanara Medtech Inc:

The MRQ is 0.653. The company is very able to pay all its debts with equity. +2
The TTM is 0.557. The company is very able to pay all its debts with equity. +2

Trends

Current period		Compared to		+/-
MRQ	0.653	TTM	0.557	+0.097
TTM	0.557	YOY	0.331	+0.226
TTM	0.557	5Y	0.455	+0.101
5Y	0.455	10Y	0.874	-0.419

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
MRQ	0.653	0.541	+0.112
TTM	0.557	0.561	-0.004
YOY	0.331	0.551	-0.220
5Y	0.455	0.653	-0.198
10Y	0.874	0.669	+0.205

Measures if Sanara Medtech Inc is able to pay off its debts by using shareholders equity.

How to use debt to equity ratio

Lower is better.
Below 2 is considered healthy (always use industry average).
Can be very different between industries.
Can be used to compare companies.

Why do investors use the debt to shareholders equity ratio in their analysis

It shows how much debt the company uses to finance their operations. Shareholders equity is whats left over when you subtract total liabilities from total assets. It's another way to meassure how much of Sanara Medtech Inc is financed with debt or own resources.

The three steps every investor should look at:

What is the current debt to equity ratio?
The current most recent quarter (MRQ) quickRatio of Sanara Medtech Inc is 0.65. This means that Sanara Medtech Inc can pay off $0.65 for each $1 in debt.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Medical Instruments & Supplies industry is 0.54.
What is the trend?
The trend is important because it shows you how Sanara Medtech Inc is performing over time. The most recent quarter might be important if Sanara Medtech Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sanara Medtech Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Not all debt is equally risky (for example, short term risk is less risky).

How to calculate debt to equity ratio

Debt to equity ratio = total debt \ shareholders equity.

Real life example Sanara Medtech Inc

You need the following data to determine equity ratio:

Balance sheet
Debt to equity ratio = total debt \ shareholders equity
29,283 \ 44,832 = 0.65 or 65.3%

Debt to equity measures the total debt versus the total shareholders equity. While the total debts to total assets ratio uses total assets, the debt to equity ratio looks at the total equity of shareholders. Where equity of shareholders are:

Common shares.
Preferred shares.
Retained earnings.

You can find the shareholders' equity in the balance sheet. A ratio between 0,5 and 1,5 is preferred. If the ratio is above 1.5, that would indicate creditors have significantly more stake (debt) in the company than the shareholders. In other words, the company is using a lot of debt to finance their operations.

Not all debt is equally risky. Meaning you can adjust the ratio by including or excluding certain amounts of debt. Short term debts are less risky because they have to be paid back within one year anyway. It’s much easier to plan one year ahead versus five or ten years.

2. Market Valuation of Sanara Medtech Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Sanara Medtech Inc generates.

Above 15 is considered overpriced but always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
A PE ratio of -369.74 means the investor is paying $-369.74 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Sanara Medtech Inc:

The EOD is -291.022. Based on the earnings, the company is expensive. -2
The MRQ is -369.738. Based on the earnings, the company is expensive. -2
The TTM is -138.481. Based on the earnings, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-291.022	MRQ	-369.738	+78.715
MRQ	-369.738	TTM	-138.481	-231.257
TTM	-138.481	YOY	-281.942	+143.461
TTM	-138.481	5Y	-123.425	-15.056
5Y	-123.425	10Y	-61.255	-62.170

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
EOD	-291.022	14.408	-305.430
MRQ	-369.738	15.934	-385.672
TTM	-138.481	16.376	-154.857
YOY	-281.942	22.147	-304.089
5Y	-123.425	20.830	-144.255
10Y	-61.255	25.069	-86.324

Measures how much money you pay for each share for every $1 in earnings Sanara Medtech Inc generates.

Indicates if the company’s shares are under or overvalued.

How to use PE ratio

Above 15 is considered overpriced but is hard to determine. Always compare Sanara Medtech Inc to the Medical Instruments & Supplies industry mean.
Can be very different between industries.
Can be used to compare companies.

Why do investors use PE ratio in their analysis

The PE ratio tells investors the current sentiment in the market for that company. As with every stock, the stock price never shows the real valuation of a company but rather how the market thinks how much the stock is worth.

In other words, the current stock price also incorporates any future earnings or business opportunities in the future. The best example is the stock market crash in 2000. The PE ratio for any internet based company was going through the roof. Only based on the general assumption the internet and all associated businesses would thrive in the future. But this was based on nothing. A business still needs a good product or service to be able to survive. Instead, every investor bought any stock which did something related to the internet. Result: huge market crash.

Many investors were willing to pay premium prices and that was causing the PE ratio to rise. A high PE ratio is a warning sign that investors might be overvaluing a stock based on future earnings.

The three steps every investor should look at:

What is the current PE Ratio?
The current most recent quarter (MRQ) PE Ratio of Sanara Medtech Inc is -369.74. This means the investor is paying $-369.74 for every $1 in earnings.
How does it compare to the industry?
The mean MRQ Quick Ratio of the Medical Instruments & Supplies industry is 15.93.
What is the trend?
The trend is important because it shows you how Sanara Medtech Inc is performing over time. The most recent quarter might be important if Sanara Medtech Inc released a new product or service. And you can use MRQ to see if they performed better vs last year. You can find all the trends for Sanara Medtech Inc up to 10 years back (depending if the company existed 10 years ago) when you exit this learning section.

Things to be aware of

Only compare with other companies in the same industry.
Some industries might have very high or very low PE ratios in general.
PE ratios can be high for several years, it does not mean a sudden collapse is imminent.
Earnings growth is not included in the PE ratio.

How to calculate PE ratio

PE ratio = market value per share \ earnings per share

Real life example Sanara Medtech Inc

You need the following data to determine the PE ratio:

Balance sheet
Income statement

The PE ratio is a very commonly used ratio to determine the value of a company by comparing the current stock price relative to its earnings per share (EPS). Before we can calculate the PE ratio we need to know the EPS. EPS is calculated as follows:

EPS = (net profit - preferred dividends) \ end of period outstanding shares*
Net profit = revenue - expenses
0 \ 8,535 = EPS
PE ratio MRQ = -369.74

* The net profit minus preferred dividends can be found in the incomestatement as netIncomeApplicableToCommonShares.

The PE value helps investors to determine if the current stock price is under or overvalued. It also projects future growth.

In general, a higher PE ratio means that investors predict higher future growth. If the PE ratio is too high, then investors expect way too much future growth the company can never fulfil. This is most likely to happen in faster moving companies like tech companies or automobile companies like Tesla. These are hot and booming markets where investors expect much future growth driven by new technology (electric cars). When looking at the current MRQ (most recent quarter) PE ratio of Tesla ( jan. 2021) it's about 247 while the average in the industry is only 6. That might be a clue that Tesla is trading for way too high prices compared to their current assets and is more based on future growth.

2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Sanara Medtech Inc:

The EOD is -76.460. Based on how much money comes from the company's main activities, the company is expensive. -2
The MRQ is -97.141. Based on how much money comes from the company's main activities, the company is expensive. -2
The TTM is -30.490. Based on how much money comes from the company's main activities, the company is expensive. -2

Trends

Current period		Compared to		+/-
EOD	-76.460	MRQ	-97.141	+20.681
MRQ	-97.141	TTM	-30.490	-66.651
TTM	-30.490	YOY	-54.793	+24.303
TTM	-30.490	5Y	-47.891	+17.401
5Y	-47.891	10Y	-23.937	-23.954

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
EOD	-76.460	9.511	-85.971
MRQ	-97.141	9.241	-106.382
TTM	-30.490	0.922	-31.412
YOY	-54.793	3.453	-58.246
5Y	-47.891	5.897	-53.788
10Y	-23.937	-0.177	-23.760

2. Book Value per Share

2.3. Price to Book Ratio

Measures if the stock price of Sanara Medtech Inc is to cheap or to expensive compared to its book value.

At or below 1 is considered healthy (always compare to Medical Instruments & Supplies industry mean).
A PB ratio of 7.87 means the investor is paying $7.87 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Sanara Medtech Inc:

The EOD is 6.193. Based on the equity, the company is overpriced. -1
The MRQ is 7.868. Based on the equity, the company is overpriced. -1
The TTM is 7.684. Based on the equity, the company is overpriced. -1

Trends

Current period		Compared to		+/-
EOD	6.193	MRQ	7.868	-1.675
MRQ	7.868	TTM	7.684	+0.184
TTM	7.684	YOY	7.133	+0.551
TTM	7.684	5Y	9.523	-1.839
5Y	9.523	10Y	4.370	+5.154

Compared to industry (Medical Instruments & Supplies)

Period	Company	Industry (mean)	+/-
EOD	6.193	2.448	+3.745
MRQ	7.868	2.753	+5.115
TTM	7.684	2.691	+4.993
YOY	7.133	3.294	+3.839
5Y	9.523	3.563	+5.960
10Y	4.370	4.227	+0.143

2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Sanara Medtech Inc.

3.1. Institutions holding Sanara Medtech Inc

Institutions are holding 8.425% of the shares of Sanara Medtech Inc.

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2023-12-31	BlackRock Inc	2.3979	0.0002	204745	23842	13.1794
2023-12-31	Vanguard Group Inc	1.6402	0.0001	140046	4403	3.246
2023-12-31	Geode Capital Management, LLC	0.8747	0.0003	74682	3939	5.568
2023-12-31	State Street Corporation	0.6254	0.0001	53399	1789	3.4664
2023-12-31	Northern Trust Corp	0.362	0.0002	30906	162	0.5269
2023-12-31	Ameriprise Financial Inc	0.1877	0.0002	16030	-2437	-13.1965
2023-12-31	Janney Montgomery Scott LLC	0.18	0.0021	15369	4520	41.6628
2023-12-31	Bank of New York Mellon Corp	0.166	0.0001	14170	3741	35.8711
2023-12-31	Diametric Capital, LP	0.1594	0.3404	13607	-3240	-19.2319
2023-12-31	Salem Investment Counselors Inc	0.1313	0.0158	11210	-2000	-15.14
2023-12-31	Morgan Stanley - Brokerage Accounts	0.1217	0	10389	5405	108.447
2023-12-31	Charles Schwab Investment Management Inc	0.121	0.0001	10332	0	0
2023-12-31	Renaissance Technologies Corp	0.1171	0.0006	10000	1200	13.6364
2023-09-30	Citadel Advisors Llc	0.1132	0.0001	9669	-8244	-46.0224
2023-12-31	Stephens Inc	0.1068	0.0065	9121	0	0
2023-12-31	Quadrature Capital LLP	0.0802	0.0051	6852	-8775	-56.1528
2023-12-31	T. Rowe Price Associates, Inc.	0.0642	0	5483	5483	0
2023-12-31	Barclays PLC	0.0625	0.0001	5336	4653	681.2592
2023-12-31	Nuveen Asset Management, LLC	0.0596	0.0001	5089	5089	0
2023-12-31	UBS Group AG	0.0514	0.0001	4391	2124	93.6921
Total		7.6223	0.3722	650826	+41654	+6.4%

3.2. Funds holding Sanara Medtech Inc

Date	Name	Total Shares	Total Assets	Current Shares	Change	%
2024-02-29	iShares Russell 2000 ETF	1.0896	0.0057	93033	-15	-0.0161
2024-02-29	Vanguard Total Stock Mkt Idx Inv	0.837	0.0002	71464	0	0
2024-02-29	Vanguard Institutional Extnd Mkt Idx Tr	0.4513	0.0014	38532	81	0.2107
2023-12-31	Fidelity Small Cap Index	0.4235	0.0059	36163	267	0.7438
2024-02-29	iShares Russell 2000 Growth ETF	0.3768	0.0108	32172	-37	-0.1149
2024-01-31	Fidelity Extended Market Index	0.2147	0.0017	18329	0	0
2024-02-29	State St Russell Sm/Mid Cp® Indx NL Cl C	0.1722	0.0013	14700	0	0
2024-02-29	Vanguard Russell 2000 ETF	0.1653	0.0056	14110	1068	8.1889
2024-02-29	State St Russell Sm Cap® Indx SL Cl I	0.1628	0.0056	13900	0	0
2023-12-31	NT R2000 Growth Index Fund - NL	0.1325	0.0126	11316	0	0
2023-12-31	NT R2000 Index Fund - NL	0.1271	0.0062	10853	19	0.1754
2024-02-29	iShares Micro-Cap ETF	0.102	0.0363	8707	0	0
2023-12-31	NT R2000 Growth Index Fund - L	0.1017	0.0129	8686	683	8.5343
2023-12-31	Northern Trust Russell 2000 Growth Index	0.1017	0.0129	8686	683	8.5343
2024-02-29	Schwab Small Cap Index	0.1016	0.0056	8678	0	0
2023-12-31	NT R2000 Index Fund - DC - NL - 2	0.1001	0.0062	8547	-18	-0.2102
2023-12-31	Russell 2000 Index Non-Lendable Fund E	0.0781	0.0061	6670	-8	-0.1198
2023-09-30	The Vanguard Russell 2000 Growth Index	0.0719	0.0107	6137	59	0.9707
2024-02-29	iShares Russell 2000 Small-Cap Idx Instl	0.0707	0.005	6035	0	0
2024-01-31	Fidelity Total Market Index	0.0627	0.0002	5356	0	0
Total		4.9433	0.1529	422074	+2782	+0.7%

3.3. Insider Transactions

Insiders are holding 60.552% of the shares of Sanara Medtech Inc.

Date	Owner	Type	Amount	Price
2022-11-08	Zachary B Fleming	SELL	417	33
2022-11-04	Zachary B Fleming	SELL	563	33
2022-11-02	Zachary B Fleming	SELL	20	33.02
2022-09-22	Shawn M Bowman	SELL	1000	27.89
2022-07-05	Zachary B Fleming	SELL	265	21.45
2022-06-28	Zachary B Fleming	SELL	69	21
2022-06-24	Zachary B Fleming	SELL	457	21
2022-06-17	Shawn M Bowman	SELL	1000	20.02
2021-10-26	Zachary B Fleming	SELL	1000	34.04
2021-10-20	Shawn M Bowman	SELL	1000	34.19
2021-10-05	Zachary B Fleming	SELL	1000	33.1
2021-09-28	Shawn M Bowman	SELL	1000	33.33

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Sanara Medtech Inc compared to the Most Recent Quarter (MRQ).

	End of day	+/-	Most Recent Quarter	Trailing 12 Months	+/-	Year-Over-Year	+/-	5 Year	+/-	10 Year	+/-
Book Value Change Per Share	-	-	0.057	0.084	-32%	0.339	-83%	0.255	-77%	0.138	-58%
Book Value Per Share	-	-	5.224	5.012	+4%	4.403	+19%	2.831	+85%	1.394	+275%
Current Ratio	-	-	1.380	1.619	-15%	2.751	-50%	3.038	-55%	2.219	-38%
Debt To Asset Ratio	-	-	0.396	0.354	+12%	0.247	+61%	0.415	-4%	1.074	-63%
Debt To Equity Ratio	-	-	0.653	0.557	+17%	0.331	+97%	0.455	+44%	0.874	-25%
Dividend Per Share	-	-	-	-	0%	0.006	-100%	0.004	-100%	0.005	-100%
Eps	-	-	-0.028	-0.126	+354%	-0.232	+737%	-0.160	+476%	-0.097	+249%
Free Cash Flow Per Share	-	-	-0.106	-0.103	-3%	-0.227	+115%	-0.151	+43%	-0.081	-23%
Free Cash Flow To Equity Per Share	-	-	-0.128	0.180	-171%	-0.249	+95%	0.185	-169%	0.096	-233%
Gross Profit Margin	-	-	1.000	1.000	0%	1.000	0%	2.730	-63%	1.445	-31%
Intrinsic Value_10Y_max	-	-	-1.652	-	-	-	-	-	-	-	-
Intrinsic Value_10Y_min	-	-	-5.332	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_max	-	-	-0.302	-	-	-	-	-	-	-	-
Intrinsic Value_1Y_min	-	-	-0.641	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_max	-	-	-0.804	-	-	-	-	-	-	-	-
Intrinsic Value_3Y_min	-	-	-1.844	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_max	-	-	-1.180	-	-	-	-	-	-	-	-
Intrinsic Value_5Y_min	-	-	-2.950	-	-	-	-	-	-	-	-
Market Cap	276115014.000	-27%	350798364.000	327710539.800	+7%	265723359.300	+32%	233101672.020	+50%	116858104.650	+200%
Net Profit Margin	-	-	-0.013	-0.073	+445%	-0.405	+2917%	-0.774	+5675%	-0.866	+6355%
Operating Margin	-	-	-0.123	-0.118	-4%	-0.280	+127%	-0.743	+502%	-0.922	+648%
Operating Ratio	-	-	1.123	1.118	+0%	1.280	-12%	1.737	-35%	1.843	-39%
Pb Ratio	6.193	-27%	7.868	7.684	+2%	7.133	+10%	9.523	-17%	4.370	+80%
Pe Ratio	-291.022	+21%	-369.738	-138.481	-63%	-281.942	-24%	-123.425	-67%	-61.255	-83%
Price Per Share	32.350	-27%	41.100	38.395	+7%	31.133	+32%	27.311	+50%	13.691	+200%
Price To Free Cash Flow Ratio	-76.460	+21%	-97.141	-30.490	-69%	-54.793	-44%	-47.891	-51%	-23.937	-75%
Price To Total Gains Ratio	563.239	-27%	715.584	-331.203	+146%	-57.183	+108%	-259.335	+136%	-129.063	+118%
Quick Ratio	-	-	0.994	1.170	-15%	2.288	-57%	2.684	-63%	1.777	-44%
Return On Assets	-	-	-0.003	-0.018	+474%	-0.095	+2849%	-0.085	+2545%	-0.191	+5841%
Return On Equity	-	-	-0.005	-0.027	+419%	-0.128	+2315%	-0.111	+1999%	-0.010	+98%
Total Gains Per Share	-	-	0.057	0.084	-32%	0.345	-83%	0.258	-78%	0.143	-60%
Usd Book Value	-	-	44588017.000	42782268.750	+4%	37583602.000	+19%	24161448.700	+85%	11896651.950	+275%
Usd Book Value Change Per Share	-	-	0.057	0.084	-32%	0.339	-83%	0.255	-77%	0.138	-58%
Usd Book Value Per Share	-	-	5.224	5.012	+4%	4.403	+19%	2.831	+85%	1.394	+275%
Usd Dividend Per Share	-	-	-	-	0%	0.006	-100%	0.004	-100%	0.005	-100%
Usd Eps	-	-	-0.028	-0.126	+354%	-0.232	+737%	-0.160	+476%	-0.097	+249%
Usd Free Cash Flow	-	-	-902808.000	-877700.500	-3%	-1938901.750	+115%	-1292735.050	+43%	-693615.800	-23%
Usd Free Cash Flow Per Share	-	-	-0.106	-0.103	-3%	-0.227	+115%	-0.151	+43%	-0.081	-23%
Usd Free Cash Flow To Equity Per Share	-	-	-0.128	0.180	-171%	-0.249	+95%	0.185	-169%	0.096	-233%
Usd Market Cap	276115014.000	-27%	350798364.000	327710539.800	+7%	265723359.300	+32%	233101672.020	+50%	116858104.650	+200%
Usd Price Per Share	32.350	-27%	41.100	38.395	+7%	31.133	+32%	27.311	+50%	13.691	+200%
Usd Profit	-	-	-237194.000	-1157349.250	+388%	-4903782.750	+1967%	-1983066.100	+736%	-1135280.600	+379%
Usd Revenue	-	-	17689813.000	16247460.500	+9%	11460711.250	+54%	7994549.300	+121%	4569806.000	+287%
Usd Total Gains Per Share	-	-	0.057	0.084	-32%	0.345	-83%	0.258	-78%	0.143	-60%
	EOD	+2 -6	MRQ	TTM	+16 -17	YOY	+23 -12	5Y	+23 -13	10Y	+20 -16

4.2. Fundamental Score

Let's check the fundamental score of Sanara Medtech Inc based on Penke's default stock scanner.

Penke's Stock Scanner

Indicator	Condition		Value
Price to Earnings Ratio (EOD)	Between	0-15	-291.022
Price to Book Ratio (EOD)	Between	0-1	6.193
Net Profit Margin (MRQ)	Greater than	0	-0.013
Operating Margin (MRQ)	Greater than	0	-0.123
Quick Ratio (MRQ)	Greater than	1	0.994
Current Ratio (MRQ)	Greater than	1	1.380
Debt to Asset Ratio (MRQ)	Less than	1	0.396
Debt to Equity Ratio (MRQ)	Less than	1	0.653
Return on Equity (MRQ)	Greater than	0.15	-0.005
Return on Assets (MRQ)	Greater than	0.05	-0.003
Total			3/10 (30.0%)

Create your own Stock Scanner

Investing is personal. The best investors buy stocks based on their own analysis. Create your personal Stock Scanner with the key performance indicators that are important to you.
Create your own Stock Scanner

4.3. Technical Score

Let's check the technical score of Sanara Medtech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	38.647
Ma 20	Greater than	Ma 50	33.368
Ma 50	Greater than	Ma 100	35.823
Ma 100	Greater than	Ma 200	36.616
Open	Greater than	Close	32.820
Total			2/5 (40.0%)

Create your own Symbol Scanner

Trading is personal. The best traders buy and sell based on their own technical analysis. Create your personal Symbol Scanner with the technical indicators that are important to you.
Create your own Symbol Scanner

Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary

Total Assets	73,871
Total Liabilities	29,283
Total Stockholder Equity	44,832

	As reported
Total Liabilities	29,283
Total Stockholder Equity	+ 44,832
Total Assets	= 73,871

Assets

Total Assets	73,871
Total Current Assets	19,006
Long-term Assets	54,865

Total Current Assets

Total Current Assets (as reported)	19,006
Cash And Cash Equivalents	5,147
Net Receivables	8,533
Inventory	4,718
Other Current Assets	608
Total Current Assets (calculated)	19,006
+/-	0

Long-term Assets

Long-term Assets (as reported)	54,865
Property Plant Equipment	3,253
Goodwill	3,602
Long Term Investments	3,084
Intangible Assets	44,926
Long-term Assets (calculated)	54,865
+/-	0

Liabilities & Shareholders' Equity

Total Current Liabilities	13,768
Long-term Liabilities	15,515
Total Stockholder Equity	44,832

Total Current Liabilities

Total Current Liabilities (as reported)	13,768
Short-term Debt	942
Short Long Term Debt	580
Accounts payable	2,002
Other Current Liabilities	10,824
Total Current Liabilities (calculated)	14,348
+/-	580

Long-term Liabilities

Long-term Liabilities (as reported)	15,515
Long term Debt	9,113
Capital Lease Obligations	2,099
Long-term Liabilities Other	4,665
Long-term Liabilities (calculated)	15,876
+/-	361

Total Stockholder Equity

Total Stockholder Equity (as reported)	44,832
Common Stock	9
Retained Earnings	-28,037
Other Stockholders Equity	72,861
Total Stockholder Equity (calculated)	44,832
+/-	0

Other

Capital Stock	9
Cash and Short Term Investments	5,147
Common Stock Shares Outstanding	8,535
Liabilities and Stockholders Equity	73,871
Net Debt	6,645
Net Invested Capital	54,526
Net Working Capital	5,238
Property Plant and Equipment Gross	4,449
Short Long Term Debt Total	11,792

Balance Sheet

Currency in USD. All numbers in thousands.

Trend

2023-12-31

2023-09-30

2023-06-30

2023-03-31

2022-12-31

2022-09-30

2022-06-30

2022-03-31

2021-12-31

2021-09-30

2021-06-30

2021-03-31

2020-12-31

2020-09-30

2020-06-30

2020-03-31

2019-12-31

2019-09-30

2019-06-30

2019-03-31

2018-12-31

2018-09-30

2018-06-30

2018-03-31

2017-12-31

2017-09-30

2017-06-30

2017-03-31

2016-12-31

2016-09-30

2016-06-30

2016-03-31

2015-12-31

2015-09-30

2015-06-30

2015-03-31

2014-12-31

2014-09-30

2014-06-30

2014-03-31

2013-12-31

2013-09-30

2013-06-30

2013-03-31

2012-12-31

2012-09-30

2012-06-30

2012-03-31

2011-12-31

2011-09-30

2011-06-30

2011-03-31

2010-12-31

2010-09-30

2010-06-30

2010-03-31

2009-12-31

2009-09-30

2009-06-30

2009-03-31

2008-12-31

2008-09-30

2008-06-30

2008-03-31

2007-12-31

2007-09-30

2007-06-30

2007-03-31

2006-12-31

2006-09-30

2006-06-30

2006-03-31

2005-12-31

2005-09-30

2005-06-30

2005-03-31

2004-12-31

2004-09-30

2004-06-30

2004-03-31

2002-03-31

2001-09-30

2001-06-30

2001-03-31

2000-12-31

2000-09-30

2000-06-30

2000-03-31

> Total Assets

1,547
1,448
1,366
1,136
1,251
1,264
1,786
1,464
503
413
640
203
203
334
333
258
258
315
333
496
499
525
427
406
406
1,189
1,113
152
283
185
4,935
4,773
4,773
6,709
7,043
6,783
6,783
9,276
7,777
3,833
3,833
3,163
2,763
1,394
1,394
1,374
1,182
977
977
2,215
1,951
1,498
1,498
259
1,519
1,392
1,392
1,569
1,799
2,171
2,171
1,990
2,108
2,218
2,173
2,299
3,690
3,042
3,042
3,480
4,313
11,117
9,525
10,090
9,652
9,826
39,018
38,785
37,928
36,396
33,934
46,478
61,477
61,035
59,967
58,279
75,474
73,871

73,871

75,474

58,279

59,967

61,035

61,477

46,478

33,934

36,396

37,928

38,785

39,018

9,826

9,652

10,090

9,525

11,117

4,313

3,480

3,042

3,690

2,299

2,173

2,218

2,108

1,990

2,171

1,799

1,569

1,392

1,519

259

1,498

1,951

2,215

977

1,182

1,374

1,394

2,763

3,163

3,833

7,777

9,276

6,783

7,043

6,709

4,773

4,935

185

283

152

1,113

1,189

406

427

525

499

496

333

315

258

333

334

203

640

413

503

1,464

1,786

1,264

1,251

1,136

1,366

1,448

1,547

> Total Current Assets

1,032
948
884
580
705
709
764
175
376
291
496
133
133
241
251
194
194
243
264
439
444
384
375
370
370
1,167
1,093
130
197
167
170
156
156
710
751
850
850
3,081
1,798
1,589
1,589
1,213
823
1,044
1,044
1,053
876
654
654
1,915
1,665
1,211
1,211
1,204
1,271
1,159
1,159
1,365
1,608
1,996
1,996
1,740
1,888
2,037
2,012
2,155
1,605
978
978
3,194
2,489
8,856
6,790
6,109
5,283
4,482
31,540
28,919
27,230
24,608
22,494
19,827
20,573
20,617
19,008
18,178
19,375
19,006

19,006

19,375

18,178

19,008

20,617

20,573

19,827

22,494

24,608

27,230

28,919

31,540

4,482

5,283

6,109

6,790

8,856

2,489

3,194

978

1,605

2,155

2,012

2,037

1,888

1,740

1,996

1,608

1,365

1,159

1,271

1,204

1,211

1,665

1,915

654

876

1,053

1,044

823

1,213

1,589

1,798

3,081

850

751

710

156

170

167

197

130

1,093

1,167

370

375

384

444

439

264

243

194

251

241

133

496

291

376

175

764

709

705

580

884

948

1,032

Cash And Cash Equivalents

0
36
0
30
0
0
0
0
0
5
0
8
8
2
9
3
3
17
1
236
129
14
41
1
1
93
6
1
105
2
6
-4
-4
22
38
51
51
206
106
4
4
0
19
46
46
136
131
45
45
1,135
850
523
523
364
199
182
182
225
443
833
833
457
151
463
261
460
646
732
732
419
161
6,612
4,022
3,305
2,120
455
27,329
24,389
22,371
18,653
16,143
12,679
10,285
8,959
7,286
6,060
6,236
5,147

5,147

6,236

6,060

7,286

8,959

10,285

12,679

16,143

18,653

22,371

24,389

27,329

455

2,120

3,305

4,022

6,612

161

419

732

646

460

261

463

151

457

833

443

225

182

199

364

523

850

1,135

131

136

106

206

-4

105

129

236

Short-term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
1,100
1,100
4,005
0
0
0
0
0
0
0
0
0
0

4,005

1,100

500

Net Receivables

861
902
865
525
697
701
615
7
376
287
30
30
30
17
25
30
30
39
44
60
57
167
61
106
106
829
857
29
24
18
37
30
30
582
626
509
509
2,468
1,179
1,145
1,145
672
213
204
204
210
137
222
222
214
316
278
278
208
457
453
453
545
582
794
794
719
864
837
1,067
1,137
915
215
215
1,380
1,100
1,335
1,246
1,418
1,842
2,267
2,512
2,495
2,285
2,990
3,555
4,097
5,539
7,004
6,541
7,211
7,497
8,533

8,533

7,497

7,211

6,541

7,004

5,539

4,097

3,555

2,990

2,285

2,495

2,512

2,267

1,842

1,418

1,246

1,335

1,100

1,380

215

915

1,137

1,067

837

864

719

794

582

545

453

457

208

278

316

214

222

137

210

204

213

672

1,145

1,179

2,468

509

626

582

857

829

106

167

287

376

615

701

697

525

865

902

861

Other Current Assets

172
9
19
0
0
0
0
2
0
0
291
0
113
135
134
0
130
86
47
47
181
0
0
0
0
12
12
0
0
83
8
0
0
0
0
0
59
109
101
0
69
231
24
0
11
80
16
0
76
2
1
0
6
106
6
0
114
100
6
0
20
109
52
26
70
64
43
0
32
856
93
162
312
473
482
612
520
497
1,021
917
625
739
1,015
1,105
1,748
486
622
608

608

622

486

1,748

1,105

1,015

739

625

917

1,021

497

520

612

482

473

312

162

856

109

100

114

106

231

101

109

181

130

134

135

113

291

172

> Long-term Assets

515
500
483
556
546
556
1,022
1,289
127
122
144
71
71
93
82
64
64
72
69
57
55
141
52
35
35
21
20
22
85
18
4,765
4,616
4,616
5,999
6,291
5,933
5,933
6,195
5,979
2,243
2,243
1,950
1,940
350
350
321
307
323
323
299
286
288
288
-945
248
233
233
204
191
175
175
251
219
181
162
144
2,085
2,064
2,064
286
1,824
2,261
2,735
3,981
4,369
5,344
7,478
9,866
10,698
11,788
11,440
26,650
40,904
40,419
40,960
40,101
56,099
54,865

54,865

56,099

40,101

40,960

40,419

40,904

26,650

11,440

11,788

10,698

9,866

7,478

5,344

4,369

3,981

2,735

2,261

1,824

286

2,064

2,085

144

162

181

219

251

175

191

204

233

248

-945

288

286

299

323

307

321

350

1,940

1,950

2,243

5,979

6,195

5,933

6,291

5,999

4,616

4,765

141

144

122

127

1,289

1,022

556

546

556

483

500

515

Property Plant Equipment

165
150
133
116
106
93
78
84
14
14
41
55
55
77
66
49
49
60
58
43
41
39
38
23
23
21
20
10
5
6
4
3
3
2
1
1
1
0
0
0
0
0
2
0
0
0
0
29
29
31
31
45
45
42
44
42
42
38
37
35
35
136
117
63
61
59
57
53
53
266
819
790
802
754
707
1,146
2,103
2,075
2,051
2,043
1,934
1,810
2,325
2,223
3,435
3,271
3,421
3,253

3,253

3,421

3,271

3,435

2,223

2,325

1,810

1,934

2,043

2,051

2,075

2,103

1,146

707

754

802

790

819

266

117

136

106

116

133

150

165

Goodwill

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
3,278
3,602
3,602
3,602
3,602
3,602

3,602

3,278

Long Term Investments

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,959
1,958
0
0
0
0
0
0
500
1,100
1,601
4,005
3,812
5,017
4,888
3,084
3,084
3,084
3,084
3,084
3,084
3,084

3,084

4,888

5,017

3,812

4,005

1,601

1,100

500

1,958

1,959

Intangible Assets

0
0
0
0
0
0
504
338
113
108
103
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,698
4,581
4,581
4,346
4,228
4,111
4,111
3,876
3,759
433
433
400
384
0
344
319
306
293
293
268
255
242
242
217
204
191
191
166
153
140
140
115
102
117
101
85
69
52
52
20
1,005
1,471
1,933
3,227
3,162
3,098
3,775
3,785
4,836
4,728
4,618
21,756
32,217
31,510
30,839
30,144
45,991
44,926

44,926

45,991

30,144

30,839

31,510

32,217

21,756

4,618

4,728

4,836

3,785

3,775

3,098

3,162

3,227

1,933

1,471

1,005

101

117

102

115

140

153

166

191

204

217

242

255

268

293

306

319

344

384

400

433

3,759

3,876

4,111

4,228

4,346

4,581

4,698

103

108

113

338

504

Long-term Assets Other

350
350
350
440
440
463
440
1,205
0
0
0
16
16
16
16
15
15
11
11
14
14
102
14
12
12
0
0
12
81
12
63
33
33
1,651
2,061
1,822
1,822
2,319
2,220
1,811
1,811
1,550
1,553
5
5
2
0
0
0
0
0
0
0
-1,204
0
0
0
0
0
0
0
0
0
0
0
0
0
0
980
20
1,824
2,261
2,735
0
0
468
437
-24,914
9,117
-19,591
-22,849
-26,650
-40,904
-40,419
-40,960
-18,178
-19,375
-19,006

-19,006

-19,375

-18,178

-40,960

-40,419

-40,904

-26,650

-22,849

-19,591

9,117

-24,914

437

468

2,735

2,261

1,824

980

-1,204

1,553

1,550

1,811

2,220

2,319

1,822

2,061

1,651

102

1,205

440

463

440

350

> Total Liabilities

1,951
2,184
2,242
2,515
2,635
2,821
3,307
3,560
612
640
757
162
162
816
869
905
905
1,242
1,399
1,767
1,943
1,986
2,014
2,220
2,220
1,744
1,622
473
1,045
1,249
1,607
2,458
2,458
4,210
4,755
3,915
3,915
3,876
2,964
7,693
7,693
5,614
6,365
5,199
5,199
5,453
6,666
3,446
3,446
2,356
2,500
2,324
2,324
2,584
2,601
2,663
2,663
2,453
2,499
2,594
2,594
2,172
2,337
2,115
479
563
2,098
1,930
1,930
4,567
6,243
4,725
2,968
4,477
4,088
3,986
3,546
4,127
4,505
6,244
5,418
11,027
16,829
19,315
18,489
17,314
31,376
29,283

29,283

31,376

17,314

18,489

19,315

16,829

11,027

5,418

6,244

4,505

4,127

3,546

3,986

4,088

4,477

2,968

4,725

6,243

4,567

1,930

2,098

563

479

2,115

2,337

2,172

2,594

2,499

2,453

2,663

2,601

2,584

2,324

2,500

2,356

3,446

6,666

5,453

5,199

6,365

5,614

7,693

2,964

3,876

3,915

4,755

4,210

2,458

1,607

1,249

1,045

473

1,622

1,744

2,220

2,014

1,986

1,943

1,767

1,399

1,242

905

869

816

162

757

640

612

3,560

3,307

2,821

2,635

2,515

2,242

2,184

1,951

> Total Current Liabilities

1,951
2,181
2,240
2,515
2,635
2,821
3,307
3,175
612
640
757
156
156
811
866
902
902
1,240
1,399
1,767
1,943
1,986
2,014
2,220
2,220
1,744
1,622
473
1,045
1,249
1,607
2,458
2,458
3,927
4,412
3,479
3,479
3,392
2,455
6,883
6,883
5,166
6,077
5,010
5,010
5,311
6,563
3,446
3,446
2,356
2,500
2,315
2,315
1,377
1,395
1,459
1,459
1,251
1,299
1,394
1,394
972
2,337
2,115
479
563
591
404
404
2,896
4,148
2,640
2,517
3,588
3,093
3,540
3,133
3,746
4,158
6,022
5,231
6,930
9,206
12,806
10,602
9,881
13,227
13,768

13,768

13,227

9,881

10,602

12,806

9,206

6,930

5,231

6,022

4,158

3,746

3,133

3,540

3,093

3,588

2,517

2,640

4,148

2,896

404

591

563

479

2,115

2,337

972

1,394

1,299

1,251

1,459

1,395

1,377

2,315

2,500

2,356

3,446

6,563

5,311

5,010

6,077

5,166

6,883

2,455

3,392

3,479

4,412

3,927

2,458

1,607

1,249

1,045

473

1,622

1,744

2,220

2,014

1,986

1,943

1,767

1,399

1,240

902

866

811

156

757

640

612

3,175

3,307

2,821

2,635

2,515

2,240

2,181

1,951

Short-term Debt

1,189
1,458
1,557
1
1,767
54
2,195
2,099
484
528
528
0
4
4
4
0
4
3
4
1,281
1,298
1,367
1,369
0
1,508
1,038
915
0
533
620
958
0
1,366
2,727
2,665
0
2,146
1,942
1,141
0
558
1,563
2,151
0
2,230
2,307
2,474
0
1,585
1,587
1,593
0
1,597
687
676
0
619
497
447
0
418
225
1,424
1,200
0
0
0
0
596
1,098
2,113
118
120
313
239
126
127
128
226
203
180
157
299
314
253
274
554
942

942

554

274

253

314

299

157

180

203

226

128

127

126

239

313

120

118

2,113

1,098

596

1,200

1,424

225

418

447

497

619

676

687

1,597

1,593

1,587

1,585

2,474

2,307

2,230

2,151

1,563

558

1,141

1,942

2,146

2,665

2,727

1,366

958

620

533

915

1,038

1,508

1,369

1,367

1,298

1,281

528

484

2,099

2,195

1,767

1,557

1,458

1,189

Short Long Term Debt

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
1,000
2,000
0
0
190
115
0
0
0
0
0
0
0
0
0
0
0
232
580

580

232

115

190

2,000

1,000

500

Accounts payable

326
319
304
355
364
300
603
326
85
55
157
0
98
98
65
0
35
63
78
45
161
70
42
0
110
83
73
94
122
187
196
0
261
285
455
0
321
315
226
0
5
245
261
0
205
206
201
0
192
367
413
0
210
301
218
0
222
251
247
0
238
123
161
225
253
229
199
117
54
185
217
338
290
140
275
271
280
314
321
438
929
733
894
1,393
1,798
1,016
1,940
2,002

2,002

1,940

1,016

1,798

1,393

894

733

929

438

321

314

280

271

275

140

290

338

217

185

117

199

229

253

225

161

123

238

247

251

222

218

301

210

413

367

192

201

206

205

261

245

226

315

321

455

285

261

196

187

122

110

161

157

326

603

300

364

355

304

319

326

Other Current Liabilities

436
403
380
2,159
504
2,467
510
749
44
57
11
0
54
693
797
0
625
865
1,205
441
483
548
602
0
601
622
634
379
390
442
43
0
831
916
20
0
1,012
1,135
1,088
0
5,418
2,469
2,641
0
1,337
1,226
2,154
0
1,041
31
5
0
2
388
5
0
0
0
0
0
0
0
752
690
226
334
392
10
350
1,613
1,818
2,185
2,108
3,135
2,579
3,143
2,725
3,304
3,611
5,381
4,121
6,041
8,013
11,100
8,550
700
1,000
10,824

10,824

1,000

700

8,550

11,100

8,013

6,041

4,121

5,381

3,611

3,304

2,725

3,143

2,579

3,135

2,108

2,185

1,818

1,613

350

392

334

226

690

752

388

1,041

2,154

1,226

1,337

2,641

2,469

5,418

1,088

1,135

1,012

916

831

442

390

379

634

622

601

602

548

483

441

1,205

865

625

797

693

749

510

2,467

504

2,159

380

403

436

> Long-term Liabilities

1,514
1,778
1,860
356
2,130
355
2,797
2,425
568
583
684
6
6
4
3
3
3
2
82
1,326
1,460
1,438
1,412
0
1,618
1,121
988
94
655
807
1,154
0
1,627
283
343
435
435
485
510
810
810
447
288
189
189
143
103
0
1,777
1,954
2,006
9
9
1,208
1,206
1,204
1,204
1,202
1,200
1,200
1,200
1,200
1,585
1,425
253
229
1,507
1,526
1,526
1,671
2,096
2,085
450
889
995
446
414
381
347
222
187
4,097
7,623
6,509
7,887
7,433
18,149
15,515

15,515

18,149

7,433

7,887

6,509

7,623

4,097

187

222

347

381

414

446

995

889

450

2,085

2,096

1,671

1,526

1,507

229

253

1,425

1,585

1,200

1,202

1,204

1,206

1,208

2,006

1,954

1,777

103

143

189

288

447

810

510

485

435

343

283

1,627

1,154

807

655

988

1,121

1,618

1,412

1,438

1,460

1,326

684

583

568

2,425

2,797

355

2,130

356

1,860

1,778

1,514

Other Liabilities

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7
26
45
64
84
104
0
77
139
90
90
90
90
0
0
3,946
7,055
6,004
6,028
5,654
0
0

5,654

6,028

6,004

7,055

3,946

139

104

> Total Stockholder Equity

-403
-736
-876
-1,379
-1,384
-1,557
-1,522
-2,096
-109
-227
-117
0
41
-482
-537
0
-647
-927
-1,066
-1,271
-1,444
-1,460
-1,587
0
-1,814
-555
-509
-321
-763
-1,064
3,328
0
2,315
2,499
2,287
0
2,869
5,400
4,813
0
-3,860
-2,451
-3,602
0
-3,806
-4,079
-5,484
0
-2,469
-141
-549
0
-825
-2,325
-1,082
0
-1,271
-884
-700
0
-423
-181
-229
103
1,694
1,736
1,592
1,112
1,112
-1,086
-1,923
6,614
6,783
5,843
5,854
6,151
35,984
35,110
33,903
30,640
29,031
36,198
45,458
41,828
41,625
41,149
44,317
44,832

44,832

44,317

41,149

41,625

41,828

45,458

36,198

29,031

30,640

33,903

35,110

35,984

6,151

5,854

5,843

6,783

6,614

-1,923

-1,086

1,112

1,592

1,736

1,694

103

-229

-181

-423

-700

-884

-1,271

-1,082

-2,325

-825

-549

-141

-2,469

-5,484

-4,079

-3,806

-3,602

-2,451

-3,860

4,813

5,400

2,869

2,287

2,499

2,315

3,328

-1,064

-763

-321

-509

-555

-1,814

-1,587

-1,460

-1,444

-1,271

-1,066

-927

-647

-537

-482

-117

-227

-109

-2,096

-1,522

-1,557

-1,384

-1,379

-876

-736

-403

Common Stock

69
69
69
70
70
70
73
73
6
6
14
0
15
15
16
0
16
16
16
16
16
16
16
0
16
25
26
27
28
28
33
0
33
35
38
0
41
57
58
0
59
63
65
0
69
78
83
0
86
88
89
0
93
107
107
0
107
109
109
0
110
111
112
113
237
237
237
237
237
2
2
4
6
6
6
6
8
8
8
8
8
8
8
8
8
8
9
9

237

113

112

111

110

109

107

Retained Earnings

-28,037

-27,800

-26,741

-24,913

-23,395

-19,116

-21,660

-18,415

-15,235

-11,406

-9,385

-8,214

-7,032

-6,786

-5,639

-4,513

-2,676

-1,213

-376

-47,469

-46,982

-46,831

-46,862

-46,868

-47,116

-47,068

-47,200

-47,435

-47,616

-46,784

-46,338

-46,159

-45,444

-45,158

-44,487

-43,165

-41,679

-39,992

-39,017

-38,312

-36,914

-37,172

-29,934

-28,868

-22,925

-20,669

-18,984

-17,075

-15,842

-15,583

-15,282

-14,773

-13,928

-13,586

-12,999

-12,773

-12,646

-12,630

-12,457

-12,252

-12,113

-11,833

-11,722

-15,866

-15,344

-15,144

-9,253

-9,135

-7,569

-6,823

-6,248

-6,068

-6,039

-5,515

-5,296

-4,964

Capital Surplus

0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,177
44,190
44,488
45,301
0
47,438
57,851
64,566
65,214
66,529
67,881
0
0

67,881

66,529

65,214

64,566

57,851

47,438

45,301

44,488

44,190

13,177

Treasury Stock

Other Stockholders Equity

4,491
4,491
4,570
4,590
4,614
4,620
5,228
5,399
9,020
9,020
15,012
0
15,149
15,148
11,174
0
11,189
11,169
11,189
11,211
11,211
11,169
11,211
0
11,201
13,007
13,684
14,500
14,491
14,491
19,137
0
19,440
21,447
22,919
0
25,837
34,211
34,689
0
33,339
34,400
34,645
0
35,143
35,834
36,113
0
40,096
43,400
43,671
0
43,718
43,727
44,406
0
44,635
45,767
45,808
0
45,852
45,912
46,005
46,059
48,381
48,331
48,403
0
48,415
-12,081
-12,014
-2,021
11,365
11,476
12,741
13,177
44,190
44,488
45,301
45,868
47,438
57,851
64,566
65,214
66,529
67,881
72,108
72,861

72,861

72,108

67,881

66,529

65,214

64,566

57,851

47,438

45,868

45,301

44,488

44,190

13,177

12,741

11,476

11,365

-2,021

-12,014

-12,081

48,415

48,403

48,331

48,381

46,059

46,005

45,912

45,852

45,808

45,767

44,635

44,406

43,727

43,718

43,671

43,400

40,096

36,113

35,834

35,143

34,645

34,400

33,339

34,689

34,211

25,837

22,919

21,447

19,440

19,137

14,491

14,500

13,684

13,007

11,201

11,211

11,169

11,211

11,189

11,169

11,189

11,174

15,148

15,149

15,012

9,020

5,399

5,228

4,620

4,614

4,590

4,570

4,491

Balance Sheet

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2001-12-31	2000-12-31	1999-12-31
Accounts Payable	2,002	1,393	438	271	338	54	225	238	222	210	192	205	5	321	261	94	110	45	35	98	326	355	402
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	0	0	0	0	-61	-70	-57	-41	-31	-22	-17	0	-86	-85	-83	-76	-42	-42	-20	222	0	0	0
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	2,099	819	425	481	599	0	0	4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Stock	9	8	8	6	11,372	237	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Surpluse	0	65,214	0	13,177	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash	5,147	8,959	18,653	455	6,612	732	463	833	182	523	45	46	4	51	-4	1	1	236	3	8	0	30	26
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	5,147	8,959	18,653	455	6,612	732	463	833	182	523	45	46	4	51	-4	1	1	236	3	8	34	30	26
Common Stock	9	8	8	6	4	237	113	110	107	93	86	69	59	41	33	27	16	16	16	15	73	70	69
Common Stock Shares Outstanding	8,279	7,907	7,342	5,735	2,133	2,172	2,086	1,097	1,073	1,054	857	688	588	358	291	220	161	161	157	91	712	693	691
Common Stock Total Equity	0	8	0	6	4	237	113	110	107	93	86	69	59	41	33	27	16	16	16	15	0	0	0
Current Deferred Revenue	0	0	0	0	0	0	0	738	617	506	628	1,238	902	0	0	-1,508	0	0	238	0	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Good Will	3,602	3,602	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	44,926	31,510	4,728	3,098	1,471	52	117	140	191	242	293	344	433	4,111	4,581	0	0	0	0	0	0	0	0
Inventory	4,718	3,549	2,048	1,148	747	465	711	348	410	403	308	454	271	290	131	100	263	97	31	95	132	0	0
Liabilities And Stockholders Equity	73,871	61,035	36,396	9,826	11,117	3,042	2,218	2,171	1,392	1,498	977	1,394	3,833	6,783	4,773	152	406	496	258	203	1,464	1,136	1,450
Long Term Debt	9,113	0	0	0	1,500	1,500	0	1,200	1,200	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Debt Total	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Investments	3,084	3,084	5,017	1,100	0	1,958	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt	6,645	-8,140	-18,227	26	-4,513	768	737	785	1,641	1,083	1,540	2,373	1,364	2,530	1,370	1,507	1,507	1,045	4	2	2,099	-28	1,052
Net Invested Capital	54,526	41,828	30,640	6,151	-3,254	2,612	447	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Receivables	8,533	7,004	2,990	2,267	1,335	215	837	794	453	278	222	204	1,145	509	30	29	106	60	30	30	7	525	891
Net Tangible Assets	0	6,716	25,912	3,053	-6,225	-10,781	-870	-1,420	-2,265	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Working Capital	5,238	7,810	18,586	942	6,216	574	-78	602	-300	-1,105	-2,791	-3,966	-5,294	-2,629	-2,301	-343	-1,849	-1,328	-708	-23	-3,000	-1,935	-903
Non Current Assets Total	54,865	40,419	11,788	5,344	2,261	2,064	181	175	233	288	323	350	2,243	5,933	4,616	22	35	57	64	71	1,289	556	529
Non Current Liabilities Other	4,665	6,509	0	90	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Current Liabilities Total	15,515	6,509	222	446	2,085	1,526	1,425	1,200	1,204	9	1,777	189	810	435	1,627	94	1,618	1,326	3	6	2,425	356	1,478
Non Currrent Assets Other	-19,006	-40,419	-11,788	-5,344	-2,261	980	181	0	0	0	0	5	1,811	1,822	33	12	12	14	15	16	1,205	440	350
Noncontrolling Interest In Consolidated Entity	0	-108	0	-310	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Current Assets	608	1,105	917	612	162	32	26	20	114	6	76	11	69	59	0	82	0	47	130	0	2	0	4
Other Current Liab	10,824	11,100	5,381	3,143	2,185	350	690	0	0	2	1,041	1,337	5,418	1,012	831	379	601	441	625	54	749	2,159	347
Other Liab	0	6,004	0	90	104	26	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Stockholder Equity	72,861	65,214	45,868	13,177	-2,082	48,415	46,059	45,852	44,635	43,718	40,096	35,143	33,339	25,837	19,440	14,500	11,201	11,211	11,189	15,149	5,399	4,590	4,491
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Gross	4,449	2,963	2,385	1,146	790	53	63	35	42	45	29	0	0	1	3	10	23	43	49	55	0	0	0
Property Plant And Equipment Net	3,253	2,223	2,043	1,146	790	53	63	35	42	45	29	0	0	1	3	10	23	43	49	55	84	116	179
Property Plant Equipment	0	1,416	2,043	1,146	790	19	63	35	42	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Retained Earnings	-28,037	-23,395	-15,235	-7,032	-2,676	-47,469	-46,868	-47,200	-46,784	-45,444	-43,165	-39,017	-37,172	-22,925	-17,075	-14,773	-12,999	-12,457	-11,833	-15,344	-7,569	-6,039	-4,938
Retained Earnings Total Equity	0	-23,395	0	-7,032	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt	580	0	0	0	0	0	1,200	414	445	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt Total	11,792	819	425	481	2,099	1,500	1,200	1,618	1,823	1,606	1,585	2,419	1,368	2,581	1,366	1,508	1,508	1,281	7	10	2,099	1	1,078
Short Term Debt	942	314	203	126	118	0	1,200	418	619	1,597	1,585	2,230	558	2,146	1,366	1,508	1,508	1,281	4	4	2,099	1	1,075
Short Term Investments	0	0	0	1,100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Assets	73,871	61,035	36,396	9,826	11,117	3,042	2,218	2,171	1,392	1,498	977	1,394	3,833	6,783	4,773	152	406	496	258	203	1,464	1,136	1,450
Total Current Assets	19,006	20,617	24,608	4,482	8,856	978	2,037	1,996	1,159	1,211	654	1,044	1,589	850	156	130	370	439	194	133	175	580	922
Total Current Liabilities	13,768	12,806	6,022	3,540	2,640	404	2,115	1,394	1,459	2,315	3,446	5,010	6,883	3,479	2,458	473	2,220	1,767	902	156	3,175	2,515	1,824
Total Liab	29,283	19,315	6,244	3,986	4,725	1,930	2,115	2,594	2,663	2,324	3,446	5,199	7,693	3,915	2,458	473	2,220	1,767	905	162	3,560	2,515	1,827
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	44,832	41,828	30,640	6,151	6,614	1,112	103	-423	-1,271	-825	-2,469	-3,806	-3,860	2,869	2,315	-321	-1,814	-1,271	-647	41	-2,096	-1,379	-377
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2002-03-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31
Accounts Payable	2,002	1,940	1,016	1,798	1,393	894	733	929	438	321	314	280	271	275	140	290	338	217	185	54	117	199	229	253	225	161	123	238	0	247	251	222	0	218	301	210	0	413	367	192	0	201	206	205	0	261	245	5	0	226	315	321	0	455	285	261	0	196	187	122	94	73	83	110	0	42	70	161	45	78	63	35	0	65	98	98	0	157	55	85	326	603	300	364	355	304	319	326
Accumulated Amortization	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Depreciation	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Accumulated Other Comprehensive Income	0	0	0	0	0	0	0	0	0	0	0	0	0	-107	0	-76	-61	-67	0	-70	-70	-66	0	-61	-57	-85	0	-41	-41	-39	0	-31	-31	-29	-736	-22	-22	-21	0	-17	-17	0	0	0	0	0	0	-86	-86	0	0	-85	-85	0	0	-83	-83	0	0	0	-76	-292	0	-42	-42	-42	0	-42	-42	-20	0	-20	-20	-4	222	222	-4	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	2,099	2,168	2,053	2,113	819	867	308	367	425	483	419	450	481	512	542	571	599	624	205	228	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Stock	9	9	8	8	8	8	8	8	8	8	8	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Capital Surpluse	0	0	67,881	66,529	65,214	64,566	57,851	47,438	0	45,301	44,488	44,190	13,177	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash	5,147	6,236	6,060	7,286	8,959	10,285	12,679	16,143	18,653	22,371	24,389	27,329	455	2,120	3,305	4,022	6,612	161	419	732	732	646	460	261	463	151	457	833	833	443	225	182	182	199	364	523	523	850	1,135	45	45	131	136	46	46	19	0	4	4	106	206	51	51	38	22	-4	-4	6	2	105	1	6	93	1	1	41	14	129	236	1	17	3	3	9	2	8	8	0	5	0	0	0	0	0	30	0	36	0
Cash And Equivalents	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash And Short Term Investments	5,147	6,236	6,060	7,286	8,959	10,285	12,679	16,143	18,653	22,371	24,389	27,329	455	2,120	3,305	4,022	6,612	161	419	732	0	646	460	261	463	151	457	833	0	443	225	182	0	199	364	523	0	850	1,135	45	0	131	136	46	0	19	0	4	0	106	206	51	0	38	22	-4	0	6	2	105	1	6	93	1	0	41	14	129	236	1	17	3	0	9	2	8	0	69	5	0	34	0	0	0	30	0	36	0
Common Stock	9	9	8	8	8	8	8	8	8	8	8	8	6	6	6	6	4	2	2	237	237	237	237	237	113	112	111	110	0	109	109	107	0	107	107	93	0	89	88	86	0	83	78	69	0	65	63	59	0	58	57	41	0	38	35	33	0	33	28	28	27	26	25	16	0	16	16	16	16	16	16	16	0	16	15	15	0	14	6	6	73	73	70	70	70	69	69	69
Common Stock Shares Outstanding	8,535	8,332	8,226	8,174	8,300	8,107	7,791	7,606	7,518	7,518	7,497	6,817	6,231	6,280	6,203	6,204	6,231	2,366	2,366	2,366	2,366	2,366	2,366	1,589	1,112	1,112	1,119	1,085	1,085	1,085	1,085	1,073	1,073	1,073	1,063	882	882	889	878	803	803	825	782	636	636	647	633	575	575	575	563	357	357	357	350	275	275	275	279	272	251	251	197	161	161	161	161	161	161	161	161	165	165	165	149	97	97	58	58	58	707	707	692	704	692	692	692	692
Common Stock Total Equity	0	0	8	8	8	8	8	8	0	8	8	8	6	6	0	6	4	2	0	2	237	237	0	237	113	112	0	111	110	109	0	108	107	107	0	106	93	89	0	88	86	83	0	72	69	65	0	59	59	58	0	55	41	38	0	35	33	33	0	28	27	26	0	17	16	16	0	16	16	16	0	16	16	16	0	15	15	14	0	6	0	0	0	0	0	0	0	0
Current Deferred Revenue	0	9,733	7,892	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,204	0	0	0	0	0	0	623	738	0	605	503	617	0	497	0	506	0	488	371	628	0	1,734	1,572	1,238	0	1,024	889	902	0	0	0	0	0	1,271	0	0	0	409	0	0	0	0	0	0	0	0	0	0	0	111	309	238	0	0	16	0	0	62	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Asset Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Deferred Long Term Liab	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Earning Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Good Will	3,602	3,602	3,602	3,602	3,602	3,278	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Intangible Assets	44,926	45,991	30,144	30,839	31,510	32,217	21,756	4,618	4,728	4,836	3,785	3,775	3,098	3,162	3,227	1,933	1,471	1,005	20	52	52	69	85	101	117	102	115	140	140	153	166	191	191	204	217	242	242	255	268	293	293	306	319	344	0	384	400	433	433	3,759	3,876	4,111	4,111	4,228	4,346	4,581	4,581	4,698	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	103	108	113	338	504	0	0	0	0	0	0
Inventory	4,718	5,021	4,421	3,432	3,549	3,734	2,312	2,171	2,048	1,552	1,538	1,179	1,148	788	863	1,009	747	800	395	346	0	0	495	614	711	821	455	348	348	577	496	410	410	609	525	403	403	492	500	308	308	459	296	454	454	567	310	271	271	413	297	290	290	87	106	131	131	120	64	69	100	217	234	263	263	273	203	78	97	172	102	31	31	82	87	95	95	105	0	0	132	140	0	0	0	0	0	0
Liabilities And Stockholders Equity	73,871	75,474	58,279	59,967	61,035	61,477	46,478	33,934	36,396	37,928	38,785	39,018	9,826	9,652	10,090	9,525	11,117	4,313	3,480	3,042	3,042	3,690	2,299	2,173	2,218	2,108	1,990	2,171	2,171	1,799	1,569	1,392	1,392	1,519	259	1,498	1,498	1,951	2,215	977	977	1,182	1,374	1,394	1,394	2,763	3,163	3,833	3,833	7,777	9,276	6,783	6,783	7,043	6,709	4,773	4,773	4,935	185	283	152	1,113	1,189	406	406	427	525	499	496	333	315	258	258	333	334	203	203	640	413	503	1,464	1,786	1,264	1,251	1,136	1,366	1,448	1,547
Long Term Debt	9,113	9,458	0	0	0	0	0	0	0	0	0	0	0	468	393	0	1,500	1,500	1,500	1,500	1,500	1,500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Debt Total	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Long Term Investments	3,084	3,084	3,084	3,084	3,084	3,084	3,084	4,888	5,017	3,812	4,005	1,601	1,100	500	0	0	0	0	0	0	1,958	1,959	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Negative Goodwill	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Debt	6,645	5,623	-4,007	-5,174	-8,140	-9,419	-12,371	-15,776	-18,227	-21,889	-23,970	-26,878	26	-1,025	-2,180	-3,452	-4,513	3,964	2,285	768	768	854	-460	-261	737	1,273	968	785	785	1,204	1,474	1,641	1,641	1,678	1,530	1,083	1,083	743	452	1,540	1,540	2,446	2,313	2,373	2,373	2,419	2,011	1,364	1,364	1,544	2,220	2,530	2,530	2,971	2,705	1,370	1,370	952	618	428	-1	909	945	1,507	1,507	1,328	1,354	1,170	1,045	3	-12	4	4	-2	6	2	2	528	523	484	2,099	2,195	54	1,767	-28	1,558	1,425	1,189
Net Invested Capital	54,526	54,007	41,149	41,625	41,828	45,458	36,198	29,031	30,640	33,903	35,110	35,984	6,151	6,437	6,426	6,783	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Receivables	8,533	7,497	7,211	6,541	7,004	5,539	4,097	3,555	2,990	2,285	2,495	2,512	2,267	1,842	1,418	1,246	1,335	1,100	1,380	215	215	915	1,137	1,067	837	864	719	794	794	582	545	453	453	457	208	278	278	316	214	222	222	137	210	204	204	213	672	1,145	1,145	1,179	2,468	509	509	626	582	30	30	37	18	24	29	857	829	106	106	61	167	57	60	44	39	30	30	25	17	30	30	30	287	376	7	615	701	697	525	865	902	861
Net Tangible Assets	0	0	7,404	7,184	6,716	9,963	14,442	24,413	25,912	33,423	31,325	32,209	3,053	2,692	2,616	4,849	-6,225	-14,296	-12,474	-12,137	1,060	1,523	1,652	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Working Capital	5,238	6,148	8,297	8,406	7,810	11,367	12,897	17,263	18,586	23,071	25,173	28,407	942	2,190	2,521	4,272	6,216	-1,659	298	574	574	1,014	1,592	1,533	-78	-449	768	602	602	309	114	-300	-300	-124	-173	-1,105	-1,105	-835	-441	-2,791	-2,791	-5,688	-4,257	-3,966	-3,966	-5,254	-3,953	-5,294	-5,294	-656	-311	-2,629	-2,629	-3,660	-3,217	-2,301	-2,301	-1,437	-1,082	-848	-343	-529	-576	-1,849	-1,849	-1,639	-1,602	-1,499	-1,328	-1,135	-997	-708	-708	-616	-570	-23	-23	-261	-349	-236	-3,000	-2,544	-2,113	-1,930	-1,935	-1,357	-1,233	-918
Non Current Assets Total	54,865	56,099	40,101	40,960	40,419	40,904	26,650	11,440	11,788	10,698	9,866	7,478	5,344	4,369	3,981	2,735	2,261	1,824	286	2,064	2,064	2,085	144	162	181	219	251	175	175	191	204	233	233	248	-945	288	288	286	299	323	323	307	321	350	350	1,940	1,950	2,243	2,243	5,979	6,195	5,933	5,933	6,291	5,999	4,616	4,616	4,765	18	85	22	20	21	35	35	52	141	55	57	69	72	64	64	82	93	71	71	144	122	127	1,289	1,022	556	546	556	483	500	515
Non Current Liabilities Other	4,665	6,845	7,433	7,887	6,509	7,055	4,097	187	0	347	90	414	90	139	77	0	0	0	0	132	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Current Liabilities Total	15,515	18,149	7,433	7,887	6,509	7,623	4,097	187	222	347	381	414	446	995	889	450	2,085	2,096	1,671	1,526	1,526	1,507	229	253	1,425	1,585	1,200	1,200	1,200	1,200	1,202	1,204	1,204	1,206	1,208	9	9	2,006	1,954	1,777	0	103	143	189	189	288	447	810	810	510	485	435	435	343	283	1,627	0	1,154	807	655	94	988	1,121	1,618	0	1,412	1,438	1,460	1,326	82	2	3	3	3	4	6	6	684	583	568	2,425	2,797	355	2,130	356	1,860	1,778	1,514
Non Currrent Assets Other	-19,006	-19,375	-18,178	-40,960	-40,419	-40,904	-26,650	-22,849	-19,591	9,117	-24,914	437	468	0	0	2,735	2,261	1,824	20	980	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-1,204	0	0	0	0	0	0	0	2	5	5	1,553	1,550	1,811	1,811	2,220	2,319	1,822	1,822	2,061	1,651	33	33	63	12	81	12	0	0	12	12	14	102	14	14	11	11	15	15	16	16	16	16	0	0	0	1,205	440	463	440	440	350	350	350
Noncontrolling Interest In Consolidated Entity	0	0	-184	-146	-108	-810	-748	-516	0	0	0	-512	-310	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Current Assets	608	622	486	1,748	1,105	1,015	739	625	917	1,021	497	520	612	482	473	312	162	93	856	32	0	43	64	70	26	52	109	20	0	6	100	114	0	6	106	6	0	1	2	76	0	16	80	11	0	24	231	69	0	101	109	59	0	0	0	0	0	8	83	0	0	12	12	0	0	0	0	181	47	47	86	130	0	134	135	113	0	291	0	0	2	0	0	0	0	19	9	172
Other Current Liab	10,824	1,000	700	8,550	11,100	8,013	6,041	4,121	5,381	3,611	3,304	2,725	3,143	2,579	3,135	2,108	2,185	1,818	1,613	350	10	392	334	226	690	752	0	0	0	0	0	0	0	5	388	2	0	5	31	1,041	0	2,154	1,226	1,337	0	2,641	2,469	5,418	0	1,088	1,135	1,012	0	20	916	831	0	43	442	390	379	634	622	601	0	602	548	483	441	1,205	865	625	0	797	693	54	0	11	57	44	749	510	2,467	504	2,159	380	403	436
Other Liab	0	0	5,654	6,028	6,004	7,055	3,946	0	0	90	90	90	90	139	77	0	104	84	64	45	26	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Stockholder Equity	72,861	72,108	67,881	66,529	65,214	64,566	57,851	47,438	45,868	45,301	44,488	44,190	13,177	12,741	11,476	11,365	-2,021	-12,014	-12,081	48,415	0	48,403	48,331	48,381	46,059	46,005	45,912	45,852	0	45,808	45,767	44,635	0	44,406	43,727	43,718	0	43,671	43,400	40,096	0	36,113	35,834	35,143	0	34,645	34,400	33,339	0	34,689	34,211	25,837	0	22,919	21,447	19,440	0	19,137	14,491	14,491	14,500	13,684	13,007	11,201	0	11,211	11,169	11,211	11,211	11,189	11,169	11,189	0	11,174	15,148	15,149	0	15,012	9,020	9,020	5,399	5,228	4,620	4,614	4,590	4,570	4,491	4,491
Preferred Stock Redeemable	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Total Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Property Plant And Equipment Gross	4,449	4,494	4,227	4,282	2,963	2,958	0	0	0	1,581	2,075	2,103	1,146	707	0	802	790	819	0	282	53	57	0	61	63	117	0	142	35	37	0	40	42	44	0	44	45	31	0	32	29	0	0	0	0	2	0	0	0	0	0	101	1	1	0	2	3	4	0	5	10	20	0	22	23	38	0	41	43	58	0	63	49	66	0	79	55	41	0	14	0	0	0	0	0	0	0	0
Property Plant And Equipment Net	3,253	3,421	3,271	3,435	2,223	2,325	1,810	1,934	2,043	2,051	2,075	2,103	1,146	707	754	802	790	819	266	53	0	57	59	61	63	117	136	35	0	37	38	42	0	44	42	45	0	31	31	29	0	0	0	0	0	2	0	0	0	0	0	1	0	1	2	3	0	4	6	5	10	20	21	23	0	38	39	41	43	58	60	49	0	66	77	55	0	41	14	14	84	78	93	106	116	133	150	165
Property Plant Equipment	0	0	1,240	1,336	1,416	2,325	1,514	1,579	2,043	1,581	2,075	1,665	1,146	707	754	802	790	819	266	282	53	57	59	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Retained Earnings	-28,037	-27,800	-26,741	-24,913	-23,395	-19,116	-21,660	-18,415	-15,235	-11,406	-9,385	-8,214	-7,032	-6,786	-5,639	-4,513	-2,676	-1,213	-376	-47,469	-47,469	-46,982	-46,831	-46,862	-46,868	-47,116	-47,068	-47,200	-47,200	-47,435	-47,616	-46,784	-46,784	-46,338	-46,159	-45,444	-45,444	-45,158	-44,487	-43,165	-43,165	-41,679	-39,992	-39,017	-39,017	-38,312	-36,914	-37,172	-37,172	-29,934	-28,868	-22,925	-22,925	-20,669	-18,984	-17,075	-17,075	-15,842	-15,583	-15,282	-14,773	-13,928	-13,586	-12,999	-12,999	-12,773	-12,646	-12,630	-12,457	-12,252	-12,113	-11,833	-11,833	-11,722	-15,866	-15,344	-15,344	-15,144	-9,253	-9,135	-7,569	-6,823	-6,248	-6,068	-6,039	-5,515	-5,296	-4,964
Retained Earnings Total Equity	0	0	-26,741	-24,913	-23,395	-19,116	-21,660	-18,415	0	-11,406	-9,385	-8,214	-7,032	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt	580	232	0	0	0	0	0	0	0	0	0	0	0	115	190	0	0	2,000	1,000	500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Short Long Term Debt Total	11,792	11,859	2,053	2,113	819	867	308	367	425	483	419	450	481	1,095	1,125	571	2,099	4,124	2,705	1,500	1,500	1,500	0	0	1,200	1,424	1,425	1,618	1,618	1,647	1,699	1,823	1,823	1,876	1,895	1,606	1,606	1,593	1,587	1,585	1,585	2,577	2,450	2,419	2,419	2,439	2,011	1,368	1,368	1,650	2,426	2,581	2,581	3,008	2,727	1,366	1,366	958	620	533	0	915	1,038	1,508	1,508	1,369	1,367	1,298	1,281	4	5	7	7	7	8	10	10	528	528	484	2,099	2,195	54	1,767	1	1,558	1,461	1,189
Short Term Debt	942	554	274	253	314	299	157	180	203	226	128	127	126	239	313	120	118	2,113	1,098	596	0	0	0	0	1,200	1,424	225	418	0	447	497	619	0	676	687	1,597	0	1,593	1,587	1,585	0	2,474	2,307	2,230	0	2,151	1,563	558	0	1,141	1,942	2,146	0	2,665	2,727	1,366	0	958	620	533	0	915	1,038	1,508	0	1,369	1,367	1,298	1,281	4	3	4	0	4	4	4	0	528	528	484	2,099	2,195	54	1,767	1	1,557	1,458	1,189
Short Term Investments	0	0	0	0	0	0	0	0	0	0	4,005	1,100	1,100	500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Temporary Equity Redeemable Noncontrolling Interests	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Assets	73,871	75,474	58,279	59,967	61,035	61,477	46,478	33,934	36,396	37,928	38,785	39,018	9,826	9,652	10,090	9,525	11,117	4,313	3,480	3,042	3,042	3,690	2,299	2,173	2,218	2,108	1,990	2,171	2,171	1,799	1,569	1,392	1,392	1,519	259	1,498	1,498	1,951	2,215	977	977	1,182	1,374	1,394	1,394	2,763	3,163	3,833	3,833	7,777	9,276	6,783	6,783	7,043	6,709	4,773	4,773	4,935	185	283	152	1,113	1,189	406	406	427	525	499	496	333	315	258	258	333	334	203	203	640	413	503	1,464	1,786	1,264	1,251	1,136	1,366	1,448	1,547
Total Current Assets	19,006	19,375	18,178	19,008	20,617	20,573	19,827	22,494	24,608	27,230	28,919	31,540	4,482	5,283	6,109	6,790	8,856	2,489	3,194	978	978	1,605	2,155	2,012	2,037	1,888	1,740	1,996	1,996	1,608	1,365	1,159	1,159	1,271	1,204	1,211	1,211	1,665	1,915	654	654	876	1,053	1,044	1,044	823	1,213	1,589	1,589	1,798	3,081	850	850	751	710	156	156	170	167	197	130	1,093	1,167	370	370	375	384	444	439	264	243	194	194	251	241	133	133	496	291	376	175	764	709	705	580	884	948	1,032
Total Current Liabilities	13,768	13,227	9,881	10,602	12,806	9,206	6,930	5,231	6,022	4,158	3,746	3,133	3,540	3,093	3,588	2,517	2,640	4,148	2,896	404	404	591	563	479	2,115	2,337	972	1,394	1,394	1,299	1,251	1,459	1,459	1,395	1,377	2,315	2,315	2,500	2,356	3,446	3,446	6,563	5,311	5,010	5,010	6,077	5,166	6,883	6,883	2,455	3,392	3,479	3,479	4,412	3,927	2,458	2,458	1,607	1,249	1,045	473	1,622	1,744	2,220	2,220	2,014	1,986	1,943	1,767	1,399	1,240	902	902	866	811	156	156	757	640	612	3,175	3,307	2,821	2,635	2,515	2,240	2,181	1,951
Total Liab	29,283	31,376	17,314	18,489	19,315	16,829	11,027	5,418	6,244	4,505	4,127	3,546	3,986	4,088	4,477	2,968	4,725	6,243	4,567	1,930	1,930	2,098	563	479	2,115	2,337	2,172	2,594	2,594	2,499	2,453	2,663	2,663	2,601	2,584	2,324	2,324	2,500	2,356	3,446	3,446	6,666	5,453	5,199	5,199	6,365	5,614	7,693	7,693	2,964	3,876	3,915	3,915	4,755	4,210	2,458	2,458	1,607	1,249	1,045	473	1,622	1,744	2,220	2,220	2,014	1,986	1,943	1,767	1,399	1,242	905	905	869	816	162	162	757	640	612	3,560	3,307	2,821	2,635	2,515	2,242	2,184	1,951
Total Permanent Equity	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Stockholder Equity	44,832	44,317	41,149	41,625	41,828	45,458	36,198	29,031	30,640	33,903	35,110	35,984	6,151	5,854	5,843	6,783	6,614	-1,923	-1,086	1,112	1,112	1,592	1,736	1,694	103	-229	-181	-423	0	-700	-884	-1,271	0	-1,082	-2,325	-825	0	-549	-141	-2,469	0	-5,484	-4,079	-3,806	0	-3,602	-2,451	-3,860	0	4,813	5,400	2,869	0	2,287	2,499	2,315	0	3,328	-1,064	-763	-321	-509	-555	-1,814	0	-1,587	-1,460	-1,444	-1,271	-1,066	-927	-647	0	-537	-482	41	0	-117	-227	-109	-2,096	-1,522	-1,557	-1,384	-1,379	-876	-736	-403
Treasury Stock	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Warrants	0	0	0	0	0	0	0	0	0	-480	-453	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Cash Flow

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2001-12-31	2000-12-31	1999-12-31
Begin Period Cash Flow	8,959	18,653	455	6,612	176	463	833	182	523	45	46	4	51	-4	1	1	236	3	8	0	37	26	204
Capital Expenditures	265	747	750	1,644	1,705	8	86	3	5	8	30	0	0	211	0	0	82	16	12	39	48	0	30
Cash And Cash Equivalents Changes	0	-9,694	0	-6,157	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	612	0	-4,892	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	-3,812	-9,694	18,197	-6,157	6,436	269	-370	651	-341	479	-1	42	-47	55	-6	0	-236	233	-5	8	-37	4	-178
Change In Working Capital	-3,279	518	-1,182	-1,178	361	706	-354	-243	-306	-166	-463	735	203	-105	524	225	142	203	115	-105	240	261	308
Change Receivables	0	-2,269	0	-961	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-1,732	-2,269	-775	-961	-324	609	-64	-503	20	-77	-42	83	382	-420	-1	-4	0	0	0	0	-6	161	160
Change To Inventory	-1,545	-517	-1,152	-720	-281	263	-420	-91	-141	-178	-98	-161	126	-159	-31	163	-167	-66	65	-52	8	0	0
Change To Liabilities	0	2,693	99	89	-85	346	-7	88	33	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Netincome	0	-636	3,692	1,297	386	88	-198	1,008	383	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	3,728	646	415	952	941	137	112	-17	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	3,675	2,371	597	291	120	84	81	61	60	56	52	61	471	472	125	14	20	22	16	24	-61	-58	-65
Dividends Paid	0	220	443	583	9,999	223	32	46	0	0	0	0	0	0	371	0	0	0	0	0	0	0	0
End Period Cash Flow	5,147	8,959	18,653	455	6,612	732	463	833	182	523	45	46	4	51	-4	1	1	236	3	8	0	30	26
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-3,511	-6,302	-5,565	-5,679	-3,873	269	-226	406	-1,208	-1,695	-1,852	-1,226	-344	-1,282	-1,296	-1,058	-463	-415	-636	-587	-772	-569	-657
Investments	-10,530	-250	-5,285	-2,744	-1,100	-1,100	-1,100	-3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	1,034	752	28,939	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	0	583	583	583	-195	-205	117	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-4,303	-8,092	-7,994	-4,445	-2,836	-601	331	-416	-1,340	-2,278	-4,148	-1,845	-12,741	-5,135	-2,303	-1,773	-543	-624	-758	-6,295	-1,674	-1,102	478
Other Cashflows From Financing Activities	18,418	-627	1,043	-9,619	12,000	208	50	-5	2,046	2,253	2,513	2,473	4,791	2,810	1,835	1,236	227	649	631	679	998	905	56
Other Cashflows From Investing Activities	0	-3,115	0	-1,100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	-3,665	2,791	427	447	188	88	-198	1,008	383	702	2,738	3,488	11,724	3,276	359	476	0	0	2	5,828	771	329	131
Sale Purchase Of Stock	0	0	-443	39	-1	0	-28	446	0	-10	0	0	0	0	-92	0	0	0	0	0	0	0	0
Stock Based Compensation	3,443	2,703	2,669	1,403	0	0	0	0	0	0	0	675	0	0	0	476	0	0	0	0	0	0	-984
Total Cash From Financing Activities	9,641	-627	28,297	622	9,800	-208	-145	245	867	2,174	1,851	897	1,633	1,759	1,290	1,536	227	649	631	679	757	588	56
Total Cash From Operating Activities	-3,246	-5,555	-4,815	-4,035	-2,167	277	-140	409	-1,203	-1,687	-1,822	-1,226	-344	-1,493	-1,296	-1,058	-381	-399	-624	-548	-724	-569	-628
Total Cashflows From Investing Activities	0	-3,512	-5,285	-2,744	-1,196	-28	-86	-3	-5	0	0	0	0	0	0	0	0	0	0	0	0	0	0

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2002-03-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31
Begin Period Cash Flow	6,236	6,060	7,286	8,959	10,285	12,679	16,143	18,653	22,371	24,389	27,329	455	2,120	3,305	4,022	6,612	161	419	742	646	646	460	261	463	151	457	531	443	443	225	283	199	199	364	342	850	850	1,135	1,364	131	131	136	399	19	19	1	1	106	106	206	1,022	38	38	22	3	6	6	2	105	1	6	93	406	41	41	14	129	236	1	17	3	9	9	2	3	8	0	5	5	0	0	0	0	30	0	36	0	26
Capital Expenditures	54	170	13	28	53	13	2,090	45	142	583	21	4	487	57	600	557	516	1,164	19	7	7	3	4	1	83	10	2	115	0	2	0	5	0	5	0	3	3	1	1	30	0	0	0	0	0	0	0	0	0	0	0	100	0	0	0	163	0	0	0	0	461	0	0	80	80	0	0	0	0	0	0	5	5	9	0	5	5	20	0	14	43	0	1	5	0	0	0	0
Cash And Cash Equivalents Changes	0	0	-1,226	-1,673	-1,326	-2,393	-3,464	-2,510	0	-2,018	-2,940	26,873	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Cash Flows Other Operating	0	0	498	-1,014	51	-1,198	1,746	13	0	-179	1,206	-1,092	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change In Cash	-1,089	176	-1,226	-1,673	-1,326	-2,393	-3,464	-2,510	-3,719	-2,018	-2,940	26,873	-1,665	-1,185	-717	-2,589	6,451	-258	-323	85	85	187	198	-202	312	-305	-74	391	391	218	-58	-16	-16	-166	23	-326	-326	-285	-229	-87	-87	-5	-262	26	26	19	-1	-102	-102	-101	-815	13	13	16	19	-10	-10	4	-102	103	-5	-86	-314	-40	-40	28	-115	-108	235	-16	17	-6	-6	7	0	8	0	-5	5	0	-8	269	181	-30	30	-36	81	-26
Change In Working Capital	-670	564	-1,582	-1,592	437	-247	598	-270	-592	-147	188	-631	-443	-237	180	-678	525	624	-499	544	51	324	136	-297	242	-291	-45	-14	68	48	-27	86	409	-205	-92	-6	-88	78	224	-49	2,884	167	-141	516	-668	100	165	85	446	203	18	-260	2,449	136	3	383	-1,032	21	45	75	185	31	52	115	1,494	151	-170	46	119	15	6	-45	-146	46	161	-130	-278	14	-16	27	332	70	-36	-126	356	-98	161	-159
Change Receivables	0	0	-720	427	-1,525	558	-722	-580	0	210	-34	-246	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Account Receivables	-1,025	-414	-720	427	-1,525	558	-722	-580	-705	210	-34	-246	-425	-424	-172	59	-286	221	-112	701	701	221	-73	-240	15	-148	-11	-216	-216	-40	-79	53	53	-100	103	35	35	-105	25	-109	-109	73	5	233	233	-58	-62	7	7	55	68	-369	-369	-9	-39	7	7	-18	5	5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	84	85	-20	-156	285	-159	206	-172
Change To Inventory	119	-723	-1,029	87	-65	-28	-229	-195	-641	-91	-382	-38	-420	-108	71	-263	53	-405	-49	119	119	46	119	98	52	-366	-153	92	92	-97	46	66	66	-84	-180	145	145	-40	-208	-93	-93	-163	31	112	112	-257	94	141	141	-8	45	-203	-203	19	24	-11	-11	-56	6	31	118	17	14	10	10	-70	-125	19	76	-70	12	52	52	5	3	9	9	0	0	0	0	0	0	0	0	0	0	0
Change To Liabilities	0	0	-692	-1,544	1,976	-1,812	-196	491	140	-87	581	-440	125	227	-354	90	1	76	-215	53	-104	-7	-31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Netincome	0	0	1,285	740	2,156	-4,784	1,030	1,112	2,273	168	25	463	106	591	171	429	58	73	24	11	8	-5	14	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Change To Operating Activities	0	0	875	-2,500	1,523	1,035	1,052	117	614	-348	600	-220	276	68	635	-565	756	732	-124	-313	-53	63	120	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Depreciation	1,095	998	804	779	814	942	412	203	201	205	101	91	82	82	74	54	47	46	23	20	20	21	22	20	-2	41	21	15	15	15	15	15	15	15	15	14	14	14	14	13	13	13	13	13	13	16	16	117	117	117	-23	118	118	115	113	119	119	2	-1	5	11	1	1	14	14	2	2	2	15	2	2	10	10	2	2	8	8	7	5	5	-17	-15	-15	-15	-16	-14	-15	-14
Dividends Paid	0	0	0	0	0	0	220	0	0	0	0	200	0	0	0	0	0	0	0	223	0	0	0	151	32	0	0	46	0	0	0	229	0	0	0	231	0	0	0	281	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	371	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
End Period Cash Flow	5,147	6,236	6,060	7,286	8,959	10,285	12,679	16,143	18,653	22,371	24,389	27,329	455	2,120	3,305	4,022	6,612	161	419	732	732	646	460	261	463	151	457	833	833	443	225	182	182	199	364	523	523	850	1,135	45	45	131	136	46	46	19	1	4	4	106	206	51	51	38	22	-4	-4	6	2	105	1	6	93	1	1	41	14	129	236	1	17	3	3	9	2	8	8	0	5	5	-8	0	0	0	30	0	81	0
Exchange Rate Changes	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Free Cash Flow	-903	894	-1,733	-1,769	-698	-1,656	-3,244	-2,157	-1,926	-2,018	-355	-1,266	-1,078	-711	-1,300	-2,589	-1,349	-1,258	-822	85	85	187	198	-202	354	-304	45	419	419	270	-146	-198	-203	-403	-422	-315	-315	-284	-409	-667	-667	-126	-448	74	76	-440	-203	240	240	-397	-311	-347	-247	-497	-465	-542	-495	-149	-180	-424	64	-136	-180	-179	-179	27	-184	-125	-85	-107	-141	-139	-139	-69	-182	-257	-257	-133	-129	-68	-186	-269	-196	-121	-18	-223	-181	-146
Investments	-54	-10,113	-13	-27	-377	-750	-2,090	-250	-1,492	-583	-2,584	-600	-1,087	-500	-500	-500	-515	-1,164	-20	502	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Issuance Of Capital Stock	-122	0	282	752	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Borrowings	0	0	0	752	752	752	0	0	0	0	0	0	0	0	583	583	-2,000	1,000	500	500	500	500	500	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-237	-1,095	-1,866	-1,216	-4,163	2,486	-3,258	-3,157	-3,557	-2,048	-1,206	-1,183	-266	-1,208	-1,130	-1,841	-1,478	-843	-352	-487	-487	-151	31	6	248	-49	79	235	235	181	-922	-446	-446	-179	-582	-285	-285	-671	-776	-1,486	-1,486	-1,688	-32	-705	-705	-1,398	-30	-5,732	-5,732	-1,066	-3,199	-1,541	-1,541	-1,685	-665	-1,233	-1,233	-259	-301	-509	-845	-341	-234	-227	-227	-127	-16	-173	-205	-139	-149	-111	-111	-125	-345	-200	-200	-5,891	-118	-86	-890	-575	-179	-29	-524	-219	-333	-26
Other Cashflows From Financing Activities	9,625	18,913	225	-656	-304	-750	-220	-103	26,962	-583	-2,605	600	-39	26	583	-11,368	7,800	1,000	500	208	0	-3	-4	136	166	-10	-2	-1	-1	-2	150	250	250	250	1,546	-10	-10	-1	181	1,047	1,047	152	285	36	36	1,372	243	575	575	203	1,861	427	427	702	1,216	1,550	129	200	78	527	420	90	113	139	139	2	69	17	320	91	158	132	132	76	106	315	315	112	133	118	400	309	181	106	406	100	263	120
Other Cashflows From Investing Activities	0	0	0	1	-324	-738	-2,054	0	0	-579	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Non Cash Items	-1,266	-388	-706	-310	7,381	338	390	527	202	133	54	38	93	270	77	8	72	80	25	8	7	-5	14	70	-216	4	-8	778	778	20	788	141	13	-30	237	384	384	51	19	700	700	458	62	2,098	2,098	841	-355	5,769	-3,067	349	2,893	658	658	938	-77	189	189	87	78	5	252	174	0	50	0	0	0	0	-14	14	-1	2	0	-2	0	69	0	5,759	0	0	432	250	35	54	165	107	5	52
Sale Purchase Of Stock	0	0	282	752	0	0	0	0	0	0	0	28,939	39	0	0	0	0	0	0	0	0	0	0	0	-194	0	0	-8	0	0	0	525	0	0	0	199	0	0	0	152	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	-802	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stock Based Compensation	861	858	1,127	597	731	683	703	585	1,817	229	298	326	530	382	97	394	0	0	0	0	0	0	0	0	0	0	0	746	0	-746	0	0	0	0	0	-293	0	191	102	-204	0	37	65	531	0	0	0	0	0	0	0	-218	0	0	148	70	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Cash From Financing Activities	-186	9,225	507	96	-304	-103	-220	-103	-443	-443	-443	28,739	13	26	583	11,368	7,800	1,000	500	-208	500	500	500	-136	0	-1	-119	-29	-29	-52	88	187	187	237	445	-11	-11	-1	180	580	580	121	185	-50	-50	462	202	40	40	-863	924	-153	-153	535	923	484	484	200	78	527	120	90	113	139	139	2	69	17	320	91	158	132	132	76	106	315	315	112	133	118	201	269	181	106	108	97	263	120
Total Cash From Operating Activities	-849	1,064	-1,720	-1,741	-645	-1,643	-1,154	-2,112	-1,784	-1,434	-334	-1,262	-591	-711	-700	-2,032	-834	-94	-803	85	85	190	203	-200	272	-294	46	419	419	272	-146	-203	-203	-398	-422	-312	-312	-283	-408	-637	-637	-126	-448	74	74	-440	-203	240	240	-397	-311	-247	-247	-497	-465	-542	-542	-149	-180	-424	-397	-136	-180	-99	-99	27	-184	-125	-85	-107	-141	-144	-144	-78	-182	-253	-253	-112	-129	-55	-143	-270	-195	-116	-18	-223	-181	-146
Total Cashflows From Investing Activities	0	0	-13	-27	-377	-750	-2,090	-294	-1,492	-583	-2,605	-604	-1,087	-500	-600	-557	-515	-1,164	-19	502	502	-3	-4	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Income Statement

Currency in USD. All numbers in thousands.

	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31	2005-12-31	2004-12-31	2001-12-31	2000-12-31	1999-12-31
Cost Of Revenue	11,528	6,361	2,311	1,617	1,209	507	806	944	892	804	793	799	800	538	1,105	417	223	193	271	80	20	1,513	1,422
Depreciation And Amortization	3,675	1,991	-20	306	130	84	81	61	60	56	52	61	471	472	125	14	20	22	16	24	-61	-58	-65
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	-7,665	-12,232	-7,376	-5,005	-2,630	-501	143	-272	-965	-2,062	-2,928	-5,252	-1,529	-2,874	-1,829	-1,759	-406	-488	-895	-301	-1,326	-898	-702
Ebitda	-3,990	-10,241	-7,396	-4,698	-2,500	-418	223	-211	-905	-2,006	-2,877	-5,191	-1,058	-2,402	-1,704	-1,745	-386	-466	-879	-277	-1,387	-956	-768
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	53,462	39,482	21,833	13,970	10,557	5,330	5,499	4,564	2,480	1,829	934	375	1,410	372	-817	-127	407	-3	-60	5	1	792	828
Income Before Tax	-4,440	-13,937	-7,994	-4,445	-2,836	-601	331	-416	-1,340	-2,278	-4,148	-1,845	-12,741	-5,135	-2,303	-1,773	-543	-624	-758	-6,137	-1,748	-1,102	-980
Income Tax Expense	-137	-5,845	-688	-62	94	13	-315	-31	199	-78	-506	-3,693	10,950	1,460	460	14	137	136	-188	5,986	-74	72	-496
Interest Expense	476	285	1	12	106	87	127	174	177	294	1,726	287	262	802	473	14	137	136	51	8	328	132	684
Interest Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Minority Interest	168	-155	72	-310	-222	-222	-222	-222	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-4,303	-8,092	-7,306	-4,383	-2,930	-601	331	-416	-1,340	-2,278	-4,148	-1,845	-12,741	-5,135	-2,303	-1,773	-543	-624	-758	-6,295	-1,530	-1,102	478
Net Income Applicable To Common Shares	0	-7,937	-7,922	-4,356	-2,814	138	192	-677	-1,609	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income From Continuing Ops	-8,341	-8,092	-7,994	-4,445	-2,836	-601	331	-416	-1,340	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Interest Income	-473	-285	-1	-12	-106	-87	-127	-174	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Operating Income Net Other	0	-1,705	0	589	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Recurring	0	0	0	30	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	-7,665	-12,232	-7,376	-5,005	-2,630	-502	120	-272	-965	-2,063	-2,928	-5,418	-5,015	-3,070	-1,842	-1,759	-406	-488	-741	-6,129	-1,448	-1,014	-702
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	72,655	58,075	31,520	20,592	14,397	6,327	6,162	5,780	4,337	4,695	4,655	6,565	4,016	3,981	2,130	2,049	1,036	678	1,072	6,214	1,469	3,319	3,089
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reconciled Depreciation	3,395	2,371	597	291	120	84	81	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Research Development	4,132	3,367	559	40	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Selling General Administrative	54,769	45,976	28,053	18,684	13,068	5,736	5,275	4,765	3,385	3,835	3,810	3,289	2,746	2,932	900	0	0	0	0	0	0	0	0
Tax Provision	0	-5,845	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Operating Expenses	61,127	51,714	29,209	18,975	13,188	5,820	5,356	4,836	3,445	3,892	3,862	5,766	3,217	3,442	1,025	1,632	813	485	801	6,134	1,449	1,806	1,666
Total Other Income Expense Net	3,225	-1,705	-618	559	-206	-25	315	31	-199	78	506	3,666	-10,950	-1,421	-460	-14	-137	-136	34	-5,828	-300	-88	-5
Total Revenue	64,990	45,843	24,144	15,587	11,767	5,838	6,305	5,508	3,372	2,633	1,726	1,174	2,210	910	288	290	631	190	211	85	21	2,305	2,251

	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30	2015-06-30	2015-03-31	2014-12-31	2014-09-30	2014-06-30	2014-03-31	2013-12-31	2013-09-30	2013-06-30	2013-03-31	2012-12-31	2012-09-30	2012-06-30	2012-03-31	2011-12-31	2011-09-30	2011-06-30	2011-03-31	2010-12-31	2010-09-30	2010-06-30	2010-03-31	2009-12-31	2009-09-30	2009-06-30	2009-03-31	2008-12-31	2008-09-30	2008-06-30	2008-03-31	2007-12-31	2007-09-30	2007-06-30	2007-03-31	2006-12-31	2006-09-30	2006-06-30	2006-03-31	2005-12-31	2005-09-30	2005-06-30	2005-03-31	2004-12-31	2004-09-30	2004-06-30	2004-03-31	2002-03-31	2001-09-30	2001-06-30	2001-03-31	2000-12-31	2000-09-30	2000-06-30	2000-03-31
Cost Of Revenue	2,883	1,751	2,188	2,126	2,369	2,229	958	805	783	518	536	474	490	448	349	330	300	285	335	23	23	116	158	211	238	230	164	331	331	212	210	272	272	197	205	130	130	235	269	109	109	239	230	277	277	209	194	247	247	374	85	193	193	297	28	593	593	98	134	310	149	49	71	15	15	70	110	27	88	26	40	156	156	39	36	56	56	23	0	0	-786	186	419	294	320	398	402	393
Depreciation And Amortization	1,095	998	804	779	-226	942	412	-177	201	205	101	91	82	82	74	54	47	46	23	20	20	21	22	20	-2	41	21	15	15	15	15	15	15	15	15	14	14	14	14	13	13	13	13	13	13	16	16	117	117	117	-23	118	118	115	113	119	119	2	-1	5	11	1	1	14	14	2	2	2	15	2	2	10	10	2	2	8	8	7	5	5	-17	-15	-15	-15	-16	-14	-15	-14
Discontinued Operations	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Ebit	-2,181	-1,588	-2,227	-1,669	-3,012	-3,122	-3,194	-2,777	-3,557	-2,048	-1,206	-1,183	-852	-1,207	-1,128	-1,803	-1,403	-737	-323	-468	-468	-144	34	76	-5	-29	119	277	277	216	-904	-394	-394	-132	-343	-250	-250	-647	-752	-3,342	-1,937	930	-276	-2,984	-2,997	-1,700	-395	70	5	-675	-541	-977	-1,039	-883	-570	-899	-906	-232	-246	-472	-826	-360	-216	-199	-199	-89	27	-145	-154	-69	-86	-308	-244	-101	-84	6	-64	-128	-104	-74	-1,025	-17	-84	34	-476	-160	-291	13
Ebitda	-1,086	-591	-1,423	-890	-3,238	-2,180	-2,782	-2,954	-3,356	-1,843	-1,105	-1,092	-770	-1,125	-1,054	-1,749	-1,355	-691	-300	-447	-447	-123	56	97	-7	13	140	292	292	231	-889	-379	-379	-117	-328	-235	-235	-633	-738	-3,329	-1,923	943	-263	-2,972	-2,984	-1,684	-379	188	123	-557	-564	-860	-921	-768	-457	-780	-787	-230	-248	-466	-816	-359	-215	-185	-185	-87	30	-143	-139	-67	-83	-297	-234	-99	-82	13	-56	-121	-99	-69	-1,043	-32	-99	19	-492	-174	-306	-1
Effect Of Accounting Charges	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Extraordinary Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Gross Profit	14,807	14,274	13,566	13,396	12,947	10,816	8,713	7,006	6,251	5,306	5,741	4,535	4,299	3,858	2,619	3,194	3,053	2,624	2,683	25	25	1,451	2,104	1,751	1,460	1,319	1,289	1,414	1,414	1,198	1,048	435	435	708	540	597	597	444	275	354	354	234	186	162	162	151	76	666	666	-240	143	425	425	-185	87	-535	-535	5	-61	-257	-74	28	4	58	58	103	190	57	-32	13	6	-103	-103	20	5	-43	-43	9	29	11	-699	89	129	388	354	128	14	296
Income Before Tax	-262	-1,095	-1,866	-1,216	-4,163	-3,232	-3,258	-3,157	-3,557	-2,048	-1,206	-1,183	-266	-1,208	-1,130	-1,841	-1,478	-843	-352	-487	-487	-151	31	6	248	-49	79	235	235	181	-922	-446	-446	-179	-582	-285	-285	-671	-776	-1,486	0	-1,687	-32	-705	-705	-1,398	-30	-5,732	-5,732	-1,066	-3,199	-1,541	-1,541	-1,685	-663	-1,233	-1,233	-259	-324	-509	-845	-341	-234	-227	-227	-127	-16	-173	-205	-141	-148	-111	-111	-123	-345	-64	0	-11,645	-118	0	-1,127	-511	-174	0	-563	-161	-282	23
Income Tax Expense	-351	-35	-38	288	7,548	-1,703	-13	-27	-8	-27	-34	-2	-606	-61	-4	26	36	54	-1	19	0	19	3	10	-265	0	-11	0	0	-8	-23	0	0	0	199	-4	0	-25	-18	-3,318	0	2,523	-335	-2,390	0	-376	-420	5,746	0	322	2,430	247	0	484	17	328	0	22	3	37	62	-22	-23	28	0	37	44	28	51	71	63	-197	0	22	261	228	0	5,764	14	12	-431	494	22	28	15	19	42	8
Interest Expense	287	188	0	0	112	110	63	380	144	194	180	1	1	1	1	8	25	46	29	19	19	7	3	61	11	20	51	42	42	42	42	52	52	47	40	39	39	49	43	1,461	1,461	95	92	111	111	74	55	56	56	69	228	317	317	319	76	334	334	27	74	38	43	3	41	28	28	37	44	28	51	36	31	13	0	11	18	22	22	5,759	14	12	151	75	67	35	33	39	9	31
Interest Income	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Minority Interest	25	35	-38	-38	-56	59	-13	-27	8	-27	-453	-2	-310	-290	-230	-226	-222	-7	-1	-1	-1	-1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income	-237	-1,060	-1,828	-1,504	-11,711	-1,529	-3,245	-3,129	-3,548	-2,020	-1,171	-1,182	-246	-1,147	-1,126	-1,837	-1,463	-837	-351	-487	-487	-151	31	6	248	-49	79	235	235	181	-922	-446	-446	-179	-582	-285	-285	-671	-776	-1,486	-1,486	-1,687	-32	-705	-705	-1,398	-30	-5,732	-5,732	-1,066	-3,199	-1,541	-1,541	-1,685	-663	-1,233	-1,233	-259	-324	-509	-845	-341	-234	-227	-227	-127	-16	-173	-205	-141	-148	-111	-111	-123	-345	-200	-200	-5,891	-118	-86	-746	-586	-174	-29	-524	-219	-333	-26
Net Income Applicable To Common Shares	0	0	-1,828	-1,178	-92	-1,470	-3,245	-3,129	-3,548	-2,020	-1,171	-1,182	-246	-1,147	-1,126	-1,837	-1,463	-837	-351	-163	-487	-151	31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Income From Continuing Ops	-262	-1,095	-1,866	-1,216	-149	-1,529	-3,258	-3,157	-3,557	-2,048	-1,206	-1,183	-266	-1,208	-1,130	-1,841	-1,478	-843	-352	-163	-487	-151	31	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Net Interest Income	-287	-188	0	0	-112	-110	-63	0	0	0	0	-1	-1	-1	-1	-8	-25	-46	-29	-5	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Operating Income Net Other	0	0	0	0	-1,152	-110	-63	-380	0	-194	-180	-100	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Non Recurring	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Operating Income	-2,181	-907	-1,866	-1,669	-3,012	-3,122	-3,194	-2,777	-3,412	-1,854	-1,026	-1,084	-852	-1,307	-1,080	-1,796	-1,463	-797	-323	-468	-468	-132	31	67	-28	-29	119	277	277	216	-904	-394	-394	-132	-343	-250	-250	-647	-752	-1,937	-1,937	-331	-276	-3,024	-2,997	-1,740	-434	-3,203	5	-752	-768	-1,039	-1,039	-952	-619	-906	-906	-237	-250	-472	-826	-360	-216	-199	-199	-89	27	-145	-154	-105	-117	-124	-244	-112	-327	-64	-64	-5,886	-104	-74	-1,060	-279	-113	34	-476	-160	-291	13
Other Items	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Operating Expenses	19,871	17,613	17,980	17,191	18,328	16,167	12,865	10,588	10,446	7,678	7,303	6,093	5,641	5,613	4,047	5,290	4,766	3,647	3,341	515	515	1,698	2,228	1,886	1,703	1,578	1,334	1,469	1,469	1,193	2,162	1,101	1,101	1,038	1,088	977	977	1,327	1,296	2,400	2,400	804	691	3,436	3,436	2,100	704	907	907	886	996	1,657	1,657	1,063	734	964	964	340	323	526	901	437	291	272	272	263	273	229	210	145	163	297	297	171	368	77	77	5,918	133	85	425	554	662	683	1,181	714	728	694
Preferred Stock And Other Adjustments	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Reconciled Depreciation	1,095	998	804	779	1,429	942	412	203	201	205	101	91	82	82	74	54	47	46	23	20	20	21	22	20	-2	41	21	15	15	15	15	15	15	15	15	14	14	14	14	13	13	13	13	13	13	16	16	117	117	117	-23	118	118	115	113	119	119	2	-1	5	11	1	1	14	14	2	2	2	15	2	2	10	10	2	2	8	8	7	5	5	-17	-15	-15	-15	-16	-14	-15	-14
Research Development	652	986	1,177	1,317	1,034	1,061	1,067	205	301	36	104	118	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Selling And Marketing Expenses	0	0	0	0	0	0	0	0	0	0	0	0	8,531	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3,946	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	43	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Selling General Administrative	16,336	13,878	13,811	12,969	14,110	12,062	10,428	9,376	9,161	6,920	6,562	13,600	13,600	5,083	3,624	4,418	4,418	3,316	2,983	472	472	1,561	2,048	1,654	1,476	1,303	1,146	1,119	2,827	964	1,936	819	819	824	868	849	849	1,074	1,013	2,290	2,290	546	447	1,595	1,595	1,091	494	500	0	395	794	1,326	1,326	631	588	252	252	240	187	210	0	387	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Tax Provision	0	0	0	0	0	-1,703	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Total Operating Expenses	16,988	15,862	15,792	15,065	15,959	13,938	11,907	9,783	9,663	7,160	6,767	5,619	5,151	5,165	3,698	4,960	4,466	3,361	3,006	492	492	1,583	2,070	1,675	1,465	1,348	1,170	1,137	1,137	982	1,951	829	829	840	883	846	846	1,091	1,027	2,291	2,291	565	462	3,159	3,159	1,890	510	660	660	512	911	1,464	1,464	767	705	371	371	242	189	216	752	388	220	256	256	192	162	202	122	118	123	141	141	132	332	21	21	5,895	133	85	361	368	243	389	861	316	326	301
Total Other Income Expense Net	1,919	682	360	453	-1,152	-110	-63	-380	-144	-194	-180	-99	586	100	-49	-67	-40	-60	0	0	19	-12	-3	-9	265	0	11	0	42	8	23	0	52	0	-199	4	36	25	18	1,912	1,912	-1,261	335	2,363	-2,292	376	420	-5,746	5,737	-322	-2,289	-226	502	-463	-12	-328	328	-22	-74	-37	-19	18	-17	-28	28	-37	-44	-28	-51	-36	-31	64	-133	-11	-243	-69	-69	-5,759	-14	0	-67	-232	-60	0	-87	-1	9	10
Total Revenue	17,690	16,025	15,753	15,522	15,316	13,045	9,671	7,811	7,033	5,824	6,277	5,009	4,789	4,306	2,967	3,524	3,353	2,909	3,017	48	48	1,566	2,262	1,962	1,698	1,549	1,453	1,745	1,745	1,410	1,258	707	707	906	745	727	727	679	544	463	463	473	416	439	439	360	270	913	913	134	228	618	618	112	115	58	58	103	74	53	75	77	75	73	73	173	300	84	56	40	46	53	53	59	41	14	14	32	29	11	-1,485	275	549	682	673	526	416	689

Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue	64,990
Cost of Revenue	-11,528
Gross Profit	53,462	53,462

Operating Income (+$)
Gross Profit	53,462
Operating Expense	-61,127
Operating Income	-7,665	-7,665

Operating Expense (+$)
Research Development	4,132
Selling General Administrative	54,769
Selling And Marketing Expenses	0
Operating Expense	61,127	58,901

Net Interest Income (+$)
Interest Income	0
Interest Expense	-476
Other Finance Cost	-3
Net Interest Income	-473

Pretax Income (+$)
Operating Income	-7,665
Net Interest Income	-473
Other Non-Operating Income Expenses	0
Income Before Tax (EBT)	-4,440	-10,890 EBIT - interestExpense = -8,141 -4,440 -3,827
Interest Expense	476
Earnings Before Interest and Taxes (EBIT)	-7,665	-3,964
Earnings Before Interest and Taxes (EBITDA)	-3,990

After tax Income (+$)
Income Before Tax	-4,440
Tax Provision	-0
Net Income From Continuing Ops	-8,341	-4,440
Net Income	-4,303
Net Income Applicable To Common Shares	0

Non-recurring Events
Discontinued Operations	0
Extraordinary Items	0
Effect of Accounting Charges	0
Other Items	0
Non Recurring	0
Other Operating Expenses	72,655
Total Other Income/Expenses Net	3,225	473

Technical Analysis of Sanara Medtech Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Sanara Medtech Inc. The general trend of Sanara Medtech Inc is BEARISH with 57.1% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Sanara Medtech Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitions	Bullish trend (-57.1%)		Bearish trend (57.1%)
Overbought to neutral	Bullish pullback	=	Bearish reversal
Upper to lower neutral	Bullish correction	=	Bearish continuation
Nuetral to oversold	Oversold	=	Oversold
Oversold to neutral	Bullish reversal	=	Bearish correction
Lower to upper neutral	Bullish continuation	=	Bearish pullback
Nuetral to overbought	Overbought	=	Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.

Score

Let's take a look at the Support & Resistance of Sanara Medtech Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 35.00 < 35.00 < 35.01.

The bearish price targets are: 31.06 > 26.06 > 26.06.

Tweet this

Sanara Medtech Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

Moving averages are lagging trend indicators.
There are many types of moving averages.
Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Sanara Medtech Inc. The current mas is .

The long score for the Moving Averages is 3/14.
The longshort score for the Moving Averages is -8/(-14 +14).

MA 20 trending down: The MA 20 is trending down. -1
Close < MA 20: The price is below the MA 20. -1
MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
MA 50 trending down: The MA 50 is trending down. -1
Close < MA 50: The price is below the MA 50. -1
MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
MA 50 > MA 200: The MA 50 is higher than the MA 200. +1
MA 100 trending up: The MA 100 is trending up. +1
Close < MA 100: The price is below the MA 100. -1
MA 100 > MA 200: The MA 100 is higher than the MA 200. +1
MA 200 trending down: The MA 200 is trending down. -1
Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving Average	Amount of candles	vs. MA 50	vs. MA 100	vs. MA 200
MA 20	20
MA 50	50	-
MA 100	100	-	-
MA 200	200	-	-	-

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Shows the moving average of the selected period.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

There are various kinds of moving averages:

Simple moving average (SMA);
Exponential moving average (EMA);
Smoothed moving average (SMMA);
Linear weighted moving average (LWMA).

The moving average looks at a certain period of time and it calculates the price average. The various types of averages are using various formulas. Don’t worry, you don’t have to memorize any formula. All moving averages are calculated automatically by basically every charting software you use. But it’s good to know how moving averages are actually calculated.

Simple moving average

SMA is calculated by summing up the price closures of the selected period. The price is then divided by the selected period. For example, when using the 21 day moving average you sum up all the closing prices for each day and divide that by 21. The result is a line on the chart representing the average. Because it’s an average in the selected timeframe, the trend is always lagging. An moving average looks like this on the chart:

Source: Tradingview.com

In this case, the blue line represents a 21 day moving average. Because the average is based on results from the past, the indicator will always lag behind. For example, when price would suddenly go up, the moving average won't immediately follow.

All other moving averages discussed below look the same on the chart. The only difference is that the line will move in different directions based on the maths behind the used indicators and the amount of days used to determine the average.

Exponential moving average

The EMA gives more weight to the latest closing prices by giving them more value in the equation. EMA is calculated by adding a certain percentage to the latest closing prices:

EMA = (CLOSE (i) * P) + (EMA (i - 1) * (1 - P))

Where:

CLOSE (i) = current period close price.
EMA (i - 1) = value of the Moving Average of a preceding period.
P = the percentage of using the price value.

Smoothed moving average

A smoothed moving average is an exponential moving average with a long lookback period. Older prices are reduced in weight but are never left out in the calculation. Unlike SMA and EMA where prices are removed when they are beyond the selected period. SMMA is a combination of the SMA and EMA. The main advantage is that it smooths out fluctuations in price.

Linear weighted moving average

The LWMA gives the latest price the highest weight and then lineary scales down with each price before that. The result is that the LWMA reacts quicker to changes in price than the SMA or EMA. The formula:

LWMA = ((Pn∗W1)+(Pn−1∗W2)+(Pn−2∗W3)...) / ∑W

Where:

P = Price for the period.
n = The most recent period, n-1 is the prior period, and n-2 is two periods prior.
W = The assigned weight to each period, with the highest weight going first and then descending linearly based on the number of periods being used.

Moving averages are widely used by many traders. Which moving average you need depends on your trading strategy. Common practise is using a combination of multiple periods. For example, the EMA21, EMA50, EMA100 and EMA200. How does that look on a chart:

Source: Tradingview.com

The lowest (purple) line on the chart represents the EMA200 then following up the EMA100, EMA50 and EMA21.

You can use moving averages to determine a trend. The 200 moving average is mostly used as a baseline for determining the current trend:

When the 200 moving average is moving up it is considered a bullish trend.
When the 200 moving average is down it is considered a bearish trend.
When moving averages are flatlined, there is no clear trend so you should look for market structure, consolidation or trend reversals. Depending on how you want to trade.

This is not set in stone. Most trading strategies use multiple moving averages each with different settings. While one strategy might use the EMA20, the other uses the SMA21. There can be hundreds of different variations. Moving averages can also be used as support and resistance. More often than not, prices will bounce on moving averages.

Sanara Medtech Inc Daily Moving Averages Chart

2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

MACD is a lagging momentum indicator.
Uses two moving averages.
Can show buy or sell signals based on momentum.
Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Sanara Medtech Inc. The current macd is -0.99302238.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sanara Medtech Inc price going up in the near term. +2
MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Sanara Medtech Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Sanara Medtech Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1

Sanara Medtech Inc Daily Moving Average Convergence/Divergence (MACD) Chart

2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.

Score

Let's take a look at the Directional Movement Index (DMI) of Sanara Medtech Inc. The current adx is 21.70.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Sanara Medtech Inc shares, leading to potential downward momentum in its price. -1
PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1

Sanara Medtech Inc Daily Directional Movement Index (DMI) Chart

2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

Parabolic SAR (stop and reverse) is a lagging trend indicator.
Shows the current trend.
Shows potential entry signals.
Shows potential exit signals.
Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Sanara Medtech Inc. The current sar is 31.51.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1

Sanara Medtech Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

Leading momentum indicator, meaning the signals are instant.
Ranges between 0 and 100.
Above 70 is considered overbought.
Below 30 is considered oversold.
Above or below 50 can also be used to determine price trend or support and resistance.
RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Sanara Medtech Inc. The current rsi is 38.65. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
Trending up: The RSI is trending up. +1

Measures the speed and change of price movements.

There are four types of indicators:

Trend indicators
Momentum indicators
Volatility indicators
Volume indicators

The RSI measures the magnitude of recent price changes to determine if the asset is overbought or oversold.

Overbought (RSI above 70) means that the trading price is above its intrinsic value. This might indicate a sell or short signal.
Oversold (RSI below 30) means that the trading price is below its intrinsic value. This might indicate a buy or long signal.
RSI levels above or below 50 can also be used to determine a trend.
RSI divergence looks at a deviation between RSI and price movement.
Can be used in many different ways.

Original usage

Keep in mind that almost every indicator can be used in different ways. Even beyond the orginal settings. The relative strength index was developed by J. Welles Wilder. Wilder recommended a smoothing period of 14 days. That means a 14 day moving average (read more about this setting below). Another quote from the wikipedia page:

Wilders also considers the RSI 50 line as both support and resistance. I recommend to always read the original settings first before using an indicator. Many traders and websites are using their own version of the indicator which might be confusing.

How you can use RSI (Divergence)

First and foremost, there is no real right or wrong usage of the RSI indicator. You can use it in any way you want. Wilder recommends using a 14 day average but you can make it 50 or 100 if you like. Just keep in mind that using an indicator is just part of a larger trading plan. In other words, it’s not recommended to do any trading or investing based on a single indicator like the RSI.

The RSI is measured on a scale between 0 and 100. From 30 till 0 is considered oversold. and from 70 -100 is overbought. The RSI is a leading indicator, meaning the signals are instant.

I like to use the RSI as a trend\momentum indicator and not as an overbought or oversold indicator. I use the middle (50) as the baseline. When prices go above RSI 50 the trend is bullish and can indicate long positions. When below 50 it is considered bearish and can indicate short positions. Other traders use the 70 and 30 levels as overbought/oversold depending on the used strategy. The RSI indicator looks like this:

Source: Tradingview.com

The general concensus is that an RSI above 70 indicates that the security is overbought. In other words, the price this security is trading for is to high and should come down. So if RSI hits 70 or above this might indicate a sell signal or taking a short position (expecting the price will go down). Although RSI above 70 indicates the security is trading above it's fair value, that does not mean the price will go down.

Use tradingview to add indicators

I highly recommend using tradingview to add indicators to a chart. It has all the indicators you can think off and can add them for free (up to three indicators) to any chart you want. You can see that the levels 30 and 70 are marked with a dotted line. If you want you can remove these lines or give it another colour using Tradingview. You can also adjust the moving average used. You can also find RSI indicators made by the community that include other settings like RSI divergences.

Tradingview

Use Tradingview to (back)test your strategies and add hundreds of indicators created by the community.

View tool on Tradingview.com

RSI divergence

RSI is not only used to determine momentum but can also spot reversals or continuations of the trend. A reversal means that the trend is going in the opposite direction. From bullish to bearish or from bearish to bullish. These reversals can be spotted by looking at the price and the direction of the RSI. When the price is going up but the RSI is going down that means there is a divergence. This is also the case when RSI goes up but price is going down.

There are four types of divergences:

Regular bullish divergence
Regular bearish divergence
Hidden bullish divergence
Hidden bearish divergence

Regular bullish divergence

With a regular bullish divergence, the price is making lower highs but the oscillator (in this case the RSI) is making higher lows. A regular bullish divergence might indicate the end of the current trend. You’ll see regular bullish divergences mostly at the end of a downtrend. But that does not mean that every regular bullish divergence is a trend reversal.

Price is making lower highs
RSI is making higher lows
Indicating bullish reversal (price might go up)

Source: Tradingview.com

Regular bearish divergence

With a regular bearish divergence the price is making higher highs but the oscillator (in this case the RSI) is making lower highs. This might indicate the end of an uptrend.

Price is making higher highs
RSI is making lower highs
Indicating bearish reversal

Source: Tradingview.com

Hidden bullish divergence

With a hidden bullish divergence, the price is making a higher low while the RSI is making a lower low. This might indicate bullish trend continuation.

Price is making higher lows
RSI is making lower lows
Indicating bullish continuation

Source: Tradingview.com

As you have noticed, you can have multiple divergences in a row.

Hidden bearish divergence

With a hidden bearish divergence, price is making lower highs but RSI is making higher highs. This might indicate bearish trend continuation.

Price is making lower highs
RSI making higher highs
Indicating bearish continuation

Source: Tradingview.com

You can find many cheatsheets of RSI divergences online. Search for "RSI divergence overview" and you'll find a lot of examples. You can print these to learn the various types of divergences.

Sanara Medtech Inc Daily Relative Strength Index (RSI) Chart

3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

Leading momentum indicator, meaning the signals are instant.
Used to determine overbought and oversold areas much like the RSI.
Ranges between 0 and 100.
Above 80 is considered overbought.
Below 20 is considered oversold.
Consists of two lines named K and D.
K compares the highest high and lowest low on the selected price range.
The D line is a moving average of the K line.
Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Sanara Medtech Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Sanara Medtech Inc price going up in the near term. +2
Trending up: The STOCH %K is trending up. +1

Sanara Medtech Inc Daily Stochastic Oscillator Chart

3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

Lagging or leading Momentum indicator
When the CCI is above zero, the price is above the historical average
When the CCI is below zero, the price is below the historical average
Used for spotting trends
- If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
- If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Sanara Medtech Inc. The current cci is -74.32788029.

Sanara Medtech Inc Daily Commodity Channel Index (CCI) Chart

3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

Lagging momentum indicator
Ranges between +100 and -100
Considered overbought above +50
Considered oversold below -50
It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Sanara Medtech Inc. The current cmo is -23.16504258.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1

Sanara Medtech Inc Daily Chande Momentum Oscillator (CMO) Chart

3.5 Williams %R

Shows the current price relative to the highest high over the last 14 days.

Lagging momentum indicator
Ranging between 0 and -100
Above -20 is considered overbought
Below -80 is considered oversold
Is prone to give false signals

Score

Let's take a look at the Williams %R of Sanara Medtech Inc. The current willr is -67.21452848.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Sanara Medtech Inc is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.

Sanara Medtech Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

Lagging volatility indicator
Uses 3 bands: one upper, one lower and one in the middle
Works best when the middle band reflects an intermediate trend (MA20).
When the price is moving closer to the upper band, the market might be overbought
When the price is moving closer to the lower band, the market might be oversold

Score

Let's take a look at the Bollinger Bands of Sanara Medtech Inc.

Sanara Medtech Inc Daily Bollinger Bands Chart

4.2 Average True Range (ATR)

Measures market volatility

Leading volatility indicator
Can be used to determine stop-loss positions
Calculated by:
- Current high minus the current low
- Current high minus the previous close
- Current low minus the previous close
The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Sanara Medtech Inc. The current atr is 1.37780161.

Sanara Medtech Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

Measures market volatility

Leading momentum indicator
Calculation:
- If the closing price is above the previous closing price: OBV = previous OBV + current volume
- If the closing price is below the previous closing price: OBV = previous OBV - current volume
- If the closing price is the same as the previous closing price than the OBV is the same.
Can be used to confirm price trends
Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Sanara Medtech Inc. The current obv is -592,216.

Sanara Medtech Inc Daily On-Balance Volume (OBV) Chart

5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

Lagging momentum indicator
Looks like RSI but uses volume as an extra metric (RSI only considers price)
Above 80 is considered overbought
Below 20 is considered oversold
Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Sanara Medtech Inc. The current mfi is 37.42.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

MFI < 50: -1

Sanara Medtech Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

Type	Notification	Date
Currently no notifications for Sanara Medtech Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

Date	Indicator	Signal
2023-12-05	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-06	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2023-12-07	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-11	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2023-12-12	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-13	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2023-12-14	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-21	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-22	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2023-12-26	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2023-12-27	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
2023-12-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
2023-12-29	RSI	SHORT ENTRY	LONG CLOSE	70 crossover to downside
2024-01-03	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
2024-01-04	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
2024-01-05	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-09	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-01-11	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-16	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-01-17	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-01-18	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-01-19	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-22	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-01-24	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-01-26	STOCH	LONG EXIT		The %K line crosses below the %D line.
	MFI	SHORT ENTRY	LONG CLOSE	20 crossover to downside
2024-01-29	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
	MFI	LONG ENTRY	SHORT CLOSE	20 crossover to upside
2024-01-30	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-01-31	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-02	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-06	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-07	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-08	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	BB	SHORT ENTRY	LONG CLOSE	Price closed above the lower band.
2024-02-09	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-13	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-02-14	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-02-15	CCI	LONG ENTRY	SHORT CLOSE	100 crossover to upside
	WILLR	LONG ENTRY	SHORT CLOSE	-20 crossover to upside
2024-02-16	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-22	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-02-23	DMI	LONG ENTRY	SHORT CLOSE	The +DI crossed the -DI to the upside. The trend is reversing to an up trend.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-02-26	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	DMI	SHORT ENTRY	LONG CLOSE	The +DI crossed the -DI to the downside. The trend is reversing to a down trend.
	SAR	SHORT ENTRY	LONG CLOSE	The price broke the SAR to the downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-27	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-02-28	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-02-29	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-01	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-05	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-06	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-11	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-14	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
2024-03-18	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
2024-03-19	STOCH	SHORT EXIT		The %K line crosses above the %D line.
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-21	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
2024-03-22	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-03-25	MACD	SHORT ENTRY	LONG CLOSE	The MACD line crosses below the signal line.
	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-03-26	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-03-27	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
2024-03-28	STOCH	LONG EXIT		The %K line crosses below the %D line.
	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-04-02	CCI	SHORT ENTRY	LONG CLOSE	-100 crossover to downside
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-04-08	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-09	BB	LONG ENTRY	SHORT CLOSE	Price closed below the lower band.
2024-04-11	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-12	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-15	STOCH	LONG EXIT		The %K line crosses below the %D line.
	WILLR	SHORT ENTRY	LONG CLOSE	-80 crossover to downside
	ATR	SHORT ENTRY	LONG CLOSE	Price closed below (close - ATR).
2024-04-17	STOCH	SHORT EXIT		The %K line crosses above the %D line.
2024-04-18	SAR	LONG ENTRY	SHORT CLOSE	The price broke the SAR to the upside.
	RSI	LONG ENTRY	SHORT CLOSE	30 crossover to upside
	CMO	LONG ENTRY	SHORT CLOSE	Zero line crossover to upside
	ATR	LONG ENTRY	SHORT CLOSE	Price closed above (close + ATR).
2024-04-19	CMO	SHORT ENTRY	LONG CLOSE	Zero line crossover to downside
2024-04-22	MACD	LONG ENTRY	SHORT CLOSE	The MACD line crosses above the signal line.
	STOCH	LONG EXIT		The %K line crosses below the %D line.
2024-04-26	STOCH	SHORT EXIT		The %K line crosses above the %D line.

6.3. Candlestick Patterns

Sanara Medtech Inc Daily Candlestick Chart

Date	Candlestick Pattern

6.4. Technical Score

Let's check the technical score of Sanara Medtech Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

Indicator	Condition		Value
Rsi	Greater than	50	38.647
Ma 20	Greater than	Ma 50	33.368
Ma 50	Greater than	Ma 100	35.823
Ma 100	Greater than	Ma 200	36.616
Open	Greater than	Close	32.820
Total			2/5 (40.0%)

Create your own Symbol Scanner

Get notifications about Sanara Medtech Inc

I send you an email if I find something interesting about Sanara Medtech Inc.

Sanara Medtech Inc Buy, Hold or Sell?

Let's analyse Sanara Medtech Inc together

Get notifications about Sanara Medtech Inc

Quick analysis of Sanara Medtech Inc (30 sec.)

What can you expect buying and holding a share of Sanara Medtech Inc? (30 sec.)

How much money do you get?

What is your share worth?

+ What do you gain per year?

For what price can you sell your share?

1. Valuation of Sanara Medtech Inc (5 min.)

$32.35

$5.22

$-5.33 - $-1.65

$-0.11 - $3.57

2. Growth of Sanara Medtech Inc (5 min.)

Is Sanara Medtech Inc growing?

How much money is Sanara Medtech Inc making?

How much money comes from the company's main activities?

3. Financial Health of Sanara Medtech Inc (5 min.)

4. Comparing to competitors in the Medical Instruments & Supplies industry (5 min.)

Industry Rankings (Medical Instruments & Supplies)

What can you expect buying and holding a share of Sanara Medtech Inc? (5 min.)

What can you expect buying and holding a share of Sanara Medtech Inc?

Speculation

Investing

How much money are you going to get?

When do you get the money?

How sure are you?

Linear %

Fundamentals of Sanara Medtech Inc

About Sanara Medtech Inc

Financial Health

Valuation

1.1. Profitability of Sanara Medtech Inc.

1.1. Profitability

1.1.1. Net Profit Margin

Trends

Compared to industry (Medical Instruments & Supplies)

1.1.2. Return on Assets

Trends

Compared to industry (Medical Instruments & Supplies)

1.1.3. Return on Equity

Trends

Compared to industry (Medical Instruments & Supplies)

1.2. Operating Efficiency of Sanara Medtech Inc.

1.2. Operating Efficiency

1.2.1. Operating Margin

Trends

Compared to industry (Medical Instruments & Supplies)

1.2.2. Operating Ratio

Trends

Compared to industry (Medical Instruments & Supplies)

1.3. Liquidity of Sanara Medtech Inc.

1.3. Liquidity

1.3.1. Current Ratio

Trends

Compared to industry (Medical Instruments & Supplies)

1.3.2. Quick Ratio

Trends

Compared to industry (Medical Instruments & Supplies)

1.4. Solvency of Sanara Medtech Inc.

1.3. Liquidity

1.4.1. Debt to Asset Ratio

Trends

Compared to industry (Medical Instruments & Supplies)

1.4.2. Debt to Equity Ratio

Trends

Compared to industry (Medical Instruments & Supplies)

2. Market Valuation of Sanara Medtech Inc

2.1. Earnings Per Share

2.1. Price to Earnings Ratio

Trends

Compared to industry (Medical Instruments & Supplies)

Sanara Medtech Inc
Buy, Hold or Sell?